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ABSTRACT 
Testing metabolic and pharmacological agents following de novo 
acute heart failure in an isolated rat heart model 
Gaurang Deshpande 
Introduction: Acute heart failureis a potentially lethal clinical emergency without any 
effective therapy. Using an isolated rat heart model, we established and validated a model of 
de novo acute heart failure to study novel putative cardioprotective therapies against acute 
heart failure, including glucose, insulin and the molecular agent sphingosine-1-phosphate 
(component of high density lipoprotein) for recovery. 
Methods: In isolated rat hearts, the protocol consisted of three phases: stabilization at 
normotensive perfusion pressure, hypotensive acute heart failure and recovery by restoring 
normotension. Low 91ucose (2.5mM) and high albumin-bound free fatty acids (1.3mM) (± 
adrenaline 10-8M) were added in the perfusate. Molecular and metabolic agents were 
administered either alone or in combination in the acute heart failure or recovery phases. 
Effects of glucose, insulin and sphingosine-1-phosphatewere observed on heart function, cell 
death and mitochondrial respiration_ 
Results: In the abse'lce of adrenaline, combination of glucose andsphingosine-1-phosphate 
during acute heart f&ilure improved functional recovery by increasing the heart rate. In the 
presence of adrenaline, glucose and sphingosine-1-phosphate administered separately were 
cardioprotective in the recovery phase by improving heart rate. The combination of 
glucose+insulin and !llucose+sphingosine-1-phosphate in the recovery phase also increased 
heart rate. Glucos9+sphingosine-1-phosphate+insulin increased heart rate and left 
ventricular developed pressure.Sphingosine-1-phosphate reduced expression of cytochrome 
C, but metabolic agents had no effect.AG490 (inhibitor of signal transducer and activator of 
transcription 3) attenuated the cardioprotective effect of sphingosine-1-phosphate 
withincreased expression of the phosphorylated inactive form of this transcription factor 
protein. 
Conclusion: We have established and validated an ex-vivo model of de novoacute heart 
failure.The combination of metabolic and molecular treatments improved heart function by 
increasingsinus node activity_ Sphingosine-1-phosphate not only improved heart rate, but 
also reduced cell death, an effect mediated via activation of signal transducer and activator 
of transcription 3. Our data provide novel principles and approaches for the treatment of 
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Section 1: Burden of cardiovascular 
diseases 
History of heart disease 
The industrial revolution originated two centuries ago and brought with it a 
comfortable lifestyle and associated diseases that are now epidemics. Despite 
comfortable lifestyles and access to excellent healthcare in many developed 
countries, mortality due to heart disease and cancer is escalating. 1,2 Cardiovascular 
disease is the number one cause of morbidity and mortality in the world,3 
predominantly in the developed countries and has also spread to the developing 
countries like India and South Africa. The previous dominance of infectious diseases 
and malnutrition as major contributors to mortality in developed countries has slowly 
changed to heart disease and cancer. Heart disease manifests itself in various 
formats such as ischemic heart disease, heart failure, valvular disease, congenital 
heart disease, hypertension, cardiomyopathies, rheumatic heart disease etc. 
History suggests that ileart disease is a complication of lifestyle changes and was 
believed to affect the richer and upper class people like the ancient Egyptians due to 
their sedentary lifestyle and very rich fatty diet.4 Heart disease, however, predates 
the ancient Egyptians. In a recent publication from Thompson et aI, the authors 
performed computed lomography (CT) scans on 137 mummies excavated from 
ancient Egypt, Peru, ancestral Puebloans (modern Southwest America) and 
Unangans of Aleutian Islands (modern Alaska)to evaluate atherosclerosis in ancient 
populations.s The scanning identified calcification of the arterial wall which was 
considered as indicative of atherosclerosis, and calcification along the expected 
course was considemd probable atherosclerosis. The authors conclude that 
20 

atherosclerosis was prevalent in mummies from all cultures, even the hunter­
gatherer cultures of Peruvians and Puebloans who predated agriculture. The use of 
fire for cooking and warmth generated smoke, inhalation of which may have been a 
key player in the pro!Jression of heart disease. Another hypothesis suggested by 
Opie et at is that hunter gatherers often did strenuous physical work and were 
exposed to hunting hazards which led to profuse bleeding and often caused 
hypotension which, coupled with elevated catecholamines, led to acute heart failure 
and often death. Heart disease is therefore not just a modern disease, but a primitive 
disease that is now the major cause of mortality in the world. 
Prevalence of heart disease 
According to World Health Organization (WHO), cardiovascular diseases account for 
around 30% of all deaths happening globally. It is estimated that by 2030, 23.3 
million people will die annually due to heart disease 
(http://www.who.int/cardiovascular diseases/en/). In Europe, cardiovascular disease 
is on the rise in youngl~r adults.? The American Heart Association (AHA) guidelines 
mention that more than 2200 Americans die of cardiovascular disease everyday, 1 
death every 39 seconcls8 ; one death out of every nine deaths is caused by heart 
failure. 
Heart disease in South Africa 
In South Africa, cardiovascular disease (CVD) is a more prevalent cause of mortality 
than Human immunodeficiency virus infection I acquired immunodeficiency 
syndrome(HIV/AIDS) in the younger population «35 years}.9 Additionally, there is an 
alarming increase in diabetes, high triglycerides, low high density lipoprotein (HDL) 
cholesterol levels, obesity and hypertension.9 Kengne et al predict that by 2030, 
heart disease and stroke will cause more deaths than any other cause including 
HIV.1o CVD claims the li'les of almost 200 people per day in South Africa.9 
Risk factors for cardiovascular disease in South Africa are predominantly high blood 
pressure, obesity, use of tobacco, high cholesterol, lack of physical activity and 
unhealthy diets. 11 The INTERHEART study aimed to evaluate the prevalence of 
myocardial infarction and found that hypertension and diabetes are the leading risk 
21 

factors of CVD in the black African population as compared to other ethnic 
groups.11.12 The data from the government sources show a growing trend in obesity 
in adolescents which is a main contributor to many other complications. These risk 
factors put an individual at risk of not only cardiovascular disease but also stroke. 
The pie charts below give a brief description of the types of heart diseases in 
developing countries from 2001. 
South Asia 
• Rheumatic heart dls.ase a Hypertensive heart dl....e 
a lnnammatory heart dJseue a Cerebrovascular dina.. 
• ischemic heart dise... 8 Other cardiovascular diseases 
Figure 1-1-1: Causes of cardiovascular death in 2001 11 
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Figure 1-1-2: Cause of death statistics for South Africa: Challenges and possibilities for 
improvement13 
Hypertension is a major risk factor in the development and progression of 
cardiovascular disease, mostly with the end stage being heart failure (HF). The 
major endpoints of hypertension are cerebral hemorrhage, uremia or congestive 
heart failure .1o.14 This, coupled with lifestyle risk factors and obesity (which is 
rampant), makes hypertension a rapidly growing perilous factor for heart failure. 
Heart failure 
The definition of heart failure has evolved with our understanding of the condition . 
The early definition of heart failure by Thomas Lewis in 1933 was: "heart failure is a 
condition in which the heart fails to discharge its contents adequately". Eugene 
Braunwald in 1980 defined heart failure as "a pathophysiological state in which an 
abnormality of cardiac function is responsible for the failure of the heart to pump 
blood at a rate commensurate with the requirements of the metabolizing tissues."15 
Heart failure has also been defined by J Cohn as "the inability of the left ventricle to 
fill or empty properly".16 However, heart failure is not limited to an impairment of 
filling and emptying . A more elaborate and detailed definition is provided by Katz: He 
defines heart failure as "a clinical syndrome in which heart disease reduces cardiac 
output, increases venous pressures and is accompanied by molecular abnormalities 
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that cause progressive deterioration of the failing heart and premature myocardial 
cell death.,,17,18 The European Society of Cardiology (ESC) defines heart failure 
clinically as "a syndrome in which patients have typical symptoms (e.g. 
breathlessness, ankle swelling and fatigue) and signs (e.g. elevated jugular venous 
pressure, pulmonary crackles and displaced apex beat) resulting from an 
abnormality of cardiac structure or function.19 
Prevalence of heart failure 
Heart failure is a rapidly progressing disease with high morbidity and mortality. In the 
United States alone, almost 5.7 million people present with heart failure every year 
and the disease accounts for 55,000 deaths every year. Heart failure costs over 
$34.4 billion to the nation8,2o In Europe, there are over 15 million patients with heart 
failure and the prevalence is high amongst the elderly. The ESC estimates that 50% 
of patients with heart failure will die within 4 years.19 
Heart failure in Africa 
Heart failure in Sub-Saharan Africa is a major contributor to morbidity and mortality 
in Africa. Causes of heart failure, however, are not the same as in the developed 
world. The western world has a high incidence of ischemic heart failure whereas 
hypertensive heart failure is widely prevalent in Africa.21 Other factors involved in the 
etiology of heart failure are rheumatic heart disease and cardiomyopathies which 
constitute a major aetiology of heart failure cases in the African continent. The other 
factor is the lack of proper healthcare amenities in the economically challenged 
countries. High prevalence of HIV and other infectious diseases also contributes to 
the pathophysiology of heart failure. 21 In the "Heart of Soweto" study conducted by 
SIiwa22 and colleagues, 43% out of the 1960 patients that presented with heart 
failure, were de novo. The majority of patients were females (57%) and the most 
common ethnicity was black Africans (88%). The women patients presented with 
factors like obesity while men were predominantly smokers, with both sexes 
presenting with an elevated heart rate. The authors point out that the community in 
general was not very educated and the lack of basic amenities in the surroundings 
coupled with low income only makes the patients' plight worse. The patients mostly 
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presented with cardiovascular risk factors like systolic and diastolic hypertension 
(60%), smoking (47%), obesity (34%) and dyslipidemia (19%). The types of heart 
failure that were principal were hypertensive heart failure , idiopathic cardiomyopathy, 
right heart failure , very few cases of ischemic cardiomyopathy and valvular 
disease.22 
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Figure 1-1-3: (Copied from) Causes of heart failure in the "Heart of Soweto" study 22 
Types of heart failure 
Heart failure can be broadly classified as chronic and acute. Chronic heart failure, as 
the name suggests, is a condition that develops over time while acute heart failure is 
a rapid deterioration of the heart's function. Acute heart failure can either be acute 
worsening of chronic heart failure called "decompensation" or can occur as new 
onset of heart failure called "de novo" acute heart failure. 23 
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CHRONIC HEART FAILURE 
Chronic heart failure is a progressive disease 
Many cardiac events will lead to chronic heart failure over time. This episode may be 
an occlusion of an artery leading to a massive infarct, a slow progression of 
hypertrophy due to increasing pressure and volume stress on the heart or a 
cardiomyopathy. The common endpoint of these aetiologies is the decline in the 
inotropy and lusitropy of the heart muscle. An infarction leads to cell death via 
apoptosis or necrosis. The compensation that occurs in the heart is to aid the heart 
muscle to pump harder so as to maintain an optimal cardiac output and homeostasis 
of the cardiovascular system. This compensation mechanism activates the 
adrenergic nervous system and preserves water and salts to maintain cardiac 
output. Besides these activations, prostaglandins and nitric oxide are activated to 
control the vascular tone. 24,25 
Neurohormonal mechanisms in heart failure 
Researchers have found that the over-expression of certain biological compounds is 
responsible for the progression of heart failure. This model of heart failure is called 
the neurohormonal model of heart failure. The heart is under the control of the 
sympathetic nervous system and the increase of heart rate during "fight or flight" 
situations is mainly regulated by the sympathetic nervous system. 26 Thus, the 
prolonged over-expression of adrenaline has a deleterious effect on the heart as the 
heart has to work harder to keep up the extra demand of blood, thus leading to or 
worsening the haemodynamic imbalance. Oxidation of circulating free fatty acids is 
upregulated in the presence of catecholamines, thus inhibiting protective glucose 
uptake. Therapy using J3- adrenergic blockers has been shown to improve outcome 
in patients with heart failure and is now standard therapy. The mechanism by which 
neurohormonal activity worsens the performance of the heart is by modulating the 
fuel consumption in the heart. The failing heart is forced to use the "expensive" free 
fatty acids as fuels to generate ATP which require more oxygen; it impairs the 
utilization of glucose as a fuel by down-regulating glycolysis, which is protective for a 
failing heart as glucose is "cheap" fue1. 24,27 Mann and Bristow24 suggest that the 
26 
neurohormonal model of heart failure is not adequate to explain the progression of 
the disease; even though the conventional therapy is to antagonize the beta 
receptors, if this model was indeed adequate, this treatment should have curbed the 
disease by now. They suggest that the beta blockers aren't blocking all the receptors 
and that many systems in the body are affected in heart failure and release many 
other neurohormonal compounds into the blood stream. Hence, the rennin-
angiotensin aldosterone system is not completely blocked, leading to disease 
progression. 24,28 
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Figure: 1 .. 1-4 Mechanisms and outcomes of sympathetic stimulation29 
LV remodeling as a progressive model of heart failure 
Left ventricular hypertrophy in response to changing conditions in the heart is 
considered to be an adaptive mechanism in times of stress to maintain optimal 
pumping function in healthy individuals. Prolonged adaptation to a stress causes 
changes in the ventricular walls, known as remodeling.3o The nature of this 
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remodeling is dependent on the type of stress imposed on the heart walls . This 
eventually contributes to the failure of the myocardium and can accelerate heart 
failure when combined with neurohormonal stimulation and/or prolonged 
haemodynamic alterations .24.31 Opie et at describe the LV remodeling in heart failure 
in 3 ways: Remodeling caused by pressure overload, remodeling caused by volume 
overload and remodeling caused by a myocardial infarction. The pressure overload­
induced remodeling involves the thickening of the cardiomyocytes (refer figure 1-1­
5), making the LV smaller and causing it to attain concentric hypertrophy. This 
adaptation is needed to pump the blood out with more force. Volume-induced 
remodeling, as the name suggests, is an adaptive mechanism when the left ventricle 
needs to pump out a large amount of blood. This causes the cardiomyocytes to 
elongate (refer figure) and creates more space within the left ventricle to store and 
pump more blood. 30 
Remodeling after a myocardial infarction happens in order to compensate for the 
loss of viable myocytes. Due to a part of the myocardium being infarcted, the 
pressure on the viable cells in the ventricles is tremendous and there is extra volume 
that needs to be pumped out as well. This causes an initial beneficial adaptation for 
the ventricle, but more ischemic insults and prolonged hemodynamic stress on this 
ventricle can cause dilation and eventually failure . 30.32 
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Figure 1-1-5: Patterns of ventricular remodeling30 
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Section 2: Acute heart failure 
The ESC defines acute heart failure as "the term used to describe the rapid onset of, 
or change in, symptoms and signs of heart failure.,,19 Acute heart failure is a complex 
condition which cannot be bound by an individual method of mechanism and/or 
treatment. It varies extensively with respect to the aetiology and pathophysiology and 
clinical presentations. Hence, the treatment of acute heart failure is as varied as the 
presentation and does not follow the one-size-fits-all ideology. 
Acute heart failure morbidity and mortality 
Acute heart failure holds the highest post-discharge cardiovascular diagnosis in 
elderly patients. Morbidity and mortality associated with AHF are high with a third of 
the patients being re-hospitalized or dead within 90 days of discharge.23 Acute heart 
failure can be broady classified into two subtypes: acute decompensation of chronic 
heart failure (ADCHF) and new onset or "de novo" acute heart failure. The first year 
mortality in patients with acute heart failure is high when a comparison is made 
between patients with acute decompensation of chronic heart failure and patients 
with new onset or "de novo" acute heart failure.2.23,33 Some of the precipitating 
factors of acute heart failure are: ADCHF, acute pulmonary oedema, hypertensive 
heart failure, cardio!Jenic shock caused by hypotension leading to hypoperfusion of 
tissue, right heart failure and superimposed acute coronary syndromes. In the United 
States alone, the percentage of patients being hospitalized for acute heart failure 
rose by 174% from 1979 to 2003 and cost the country a massive amount of $15.4 
billion. 34 In Europe, data from various registries indicate that acute coronary 
syndromes are the major cause of AHF with in-hospital mortality being highest in 
patients with cardiogenic shock (40-60%). Almost 50% of the patients were re-
hospitalized within 12 months.35 
In an independent study performed in Finland, Lassus et al. examined the long term 
survival in patients3fter hospitalization for acute heart failure between ADCHF and 
de novo heart failure. 2 They observed that both groups had a high mortality in the 
first year post-hospitalization, with ADCHF patients faring worse. This mortality, 
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however, was reduced in the de novo AHF patients in the subsequent years (75.6% 
vs. 44.4%). The ADCHF group patients had a higher mortality over a 5 year period 
compared to the de novo patients. 2 
Statistics of acute heart failure in Africa 
Very few studies look at prevalence of acute heart failure in sub-Saharan Africa . 
Damasceno et al. 36 started the THESUS-HF trial where they examined 1006 patients 
from 9 countries. The participating countries were Senegal, Sudan, Ethiopia, Nigeria, 
Kenya, Uganda, Cameroon, Mozambique and South Africa. Their preliminary 
findings were that patients presenting with acute heart failure had a mean age of 
52.3 yrs , were mostly black African women (50.8%) and almost 46% of the cases 
presented with hypertension as the cause of acute heart failure, while rheumatic and 
ischemic heart disease accounted for 14.3 and 7.7% respectively . One of the major 
reasons for this is the lack of proper medical attention in the subcontinent and the 
poor economic background of patients. The table below summarizes the causes of 
acute heart failure in sub-Saharan Africa. 36 Amongst rural Nigerians, prevalence of 
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The study is the first of its kind to assess acute heart failure in the African continent. 
The results suggest that the disease affects members of both sexes equally even 
though the causes are different. The most important finding of this study is 
hypertension bein~1 the prime cause of acute heart failure and not ischemic heart 
disease as in the developed world.36 
Aetiology of acute heart failure 
Causes of acute heart failure can broadly be classified into three categories: 
worsening of chronic heart failure (acute decompensation), ischemic acute heart 
failure and non ischemic acute heart failure. 38 Despite the cause, the major finding in 
all acute heart faiiure patients is the systemic and pulmonary congestion with or 
without decreased cardiac outpUt.39 Post-discharge mortality of acute heart failure 
patients remains high, the solution to which may lie in the proper classification of the 
patients based on aetiology. The majority of patients coming into the emergency 
room with acute beart failure have a worsening of chronic heart failure; however, 
there are other factors like coronary heart disease, valve disease and hypertension 
as well as non-ischemic conditions like renal failure, diabetes and anaemia that can 
cause acute heart failure. 39 Ischemia may cause acute heart failure; however, 
ischemia may be caused by acute heart failure as well. Acute decompensation may 
be caused by a factor completely independent of CAD and worse of all, all these 
complexities may be present in a patient presenting with acute heart failure. Such 
complex presentations of the disease warrant proper classification of patients and 
development of t3ilor-made therapies.4o Acute heart failure can manifest itself 
independent of ischemic or non-ischemic causes, called "de novo" or new onset 
acute heart failure. One of the examples of this condition is Takotsubo 
cardiomyopathy, also known as "apical ballooning syndrome" or "broken heart 
syndrome". Patients with Takotsubo cardiomyopathy have elevated dilation of the left 
ventricular wall near the apex. This is thought to be caused by high circulating 
catecholamines and in some cases may cause necrosis by cyclic adenosine mono-
phosphate (cAMP)-mediated calcium overload.41 The numerous amounts of 
precipitating caUSBS for the same disease and the lack of time in the emergency 
room contribute to high mortality associated with acute heart failure. 
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Pathophysiology of heart failure 
Acute heart failurE' involves severe and dire hemodynamic and neurohormonal 
changes that mayor may not cause myocyte death. These abnormalities may be 
caused by cardiac (example: atrial fibrilliation) or non-cardiac (example: renal failure) 
factors. A consistent finding in the majority AHF patients is elevated left ventricular 
diastolic pressure, which mayor may not be accompanied by reduced cardiac 
output. This is caused by severe pulmonary congestion observed in patients with 
diastolic dysfunction.39 In patients with worsening of chronic heart failure, 
neurohormonal factors play a pivotal role in the progression of the disease. The 
activation of the renin-angiotensin aldosterone system (RAAS) and the sympathetic 
nervous system in patients with left ventricular dysfunction causing reduced output 
increases peripheral vascular resistance and hence causes an increase in 
afterload.42 This in turn leads to increased preload and a vicious cycle begins which 
worsens the condition of the left ventricle. Presence of catecholamines also leads to 
tachycardia which is deleterious by causing cell death and leading to more 
myocardial damage. SystOliC pressure measurement is a promising marker to 
differentiate the pcltients with high risk for mortality vs. those with low risk. Lower 
systolic pressures were associated with high in-hospital mortality in the OPTIMIZE-
HF registry and have been confirmed by the consistent data from the EuroHeart 
Failure Survey II where cardiogenic shock associated with hypotension and lower 
blood pressures were associated with increased mortality_ 43,44 
Figure 1·2·2: In-hospital mortality rates by admission systolic pressures43 
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Myocardial damage in acute heart failure 
Hemodynamic alterations leading to acute heart failure are associated with acute 
coronary syndromes and ischemic heart disease. The severity of an infarction and 
coronary artery disease may be the trigger for acute heart failure or vice versa. 
Especially in de novo acute heart failure patients, acute coronary syndromes playa 
pivotal role as a pathogenic mechanism leading to acute heart failure. A proposed 
pathway by Metra t9t al.23 is described here (Fig1-2-3): 
An episode of de novo acute heart failure coupled with hemodynamic abnormalities 
and the neurohormonal pathway may lead to hypotension, increased wall stress, and 
elevated heart rate owing to the elevated catecholamines which rapidly deteriorates 
the cardiac perfusion and may cause the myocardium to undergo necrosis. This 
mechanism supports the notion that reduced systolic blood pressure predicts higher 
in-hospital mortality.23,43 
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Figure 1-2-3: Mechanisms of myocardial damage in patients with AHF23 
Possible molecular and cellular mechanisms in acute heart failure 
A number of aetiologies and precipitating factors for acute heart failure and the lack 
of basic research make it very tedious to pinpoint the exact mechanisms involved. 
However, there are a few proposed hypotheses for progression of Takotsubo 
cardiomyopathy. Takotsubo cardiomyopathy is an acute heart failure syndrome 
which is characterized by dilation of the left ventricular wall and reduction of 
33 
contractility of the apex and midventricular regions. 45 The hypothesis that this is 
caused by a supra-physiological level of circulating plasma catecholamines has 
stood the test of time. One explanation of the sympathetic overdrive and myocardial 
hypoperfusion ob~,erved in patients with Takotsubo cardiomyopathy is ischemia. 
Stress can cause vasoconstriction in patients without coronary disease. This is 
supported by observations by Kurisu et al., who noticed coronary spasms in over 
70% patients in stressful situations.46,47 Another proposed mechanism is cell death 
due to elevated catecholamines. The mechanism suggested by Wittstein et at6 
involves catecholamine-mediated myocardial stunning by reducing myocyte viability, 
caused by increasing the calcium in the cells mediated by cyclic AMP. 
Catecholamines are sources of ROS and may cause cell death by attenuating anti-
oxidants, by manipulating the sodium and calcium transporters and thus causing a 
calcium influx in the cell leading to death. 
These mechanism::; are proposed and need further research before they can be 
confirmed. The heterogeneity of the disease and the multiple causes and effects 
make it difficult to zero in on a mechanism that will improve our understanding of the 
disease. 
This thesis is focused on the molecular and cellular mechanisms involved in the 
recovery after an episode of de novo acute heart failure on an isolated rat heart and 
will examine the effects of different molecular and metabolic agents on recovery. 
This will hopefully provide an insight into the treatment and the pathophysiology of 
de novo acute heart failure. 
Our model of acute heart failure 
There are growing data regarding the clinical trials and registries in acute heart 
failure, but the mechanisms and metabolism involved remains elusive. Keeping this 
in mind, we established a model of de novo acute heart failure using an isolated rat 
heart on the Langeridorff retrograde perfusion apparatus. 
Since reduced systolic pressure is associated with worse outcomes, our animal 
model of acute heart failure induces failure on the isolated rat heart by lowering the 
perfUSion pressure and changing the substrate content from glucose to fatty acids in 
the presence of admnaline to mimic the effects of neurohormonal stimulation. We 
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notice reduced coronary perfusion and left ventricular parameters and heart rate are 
the endpoints. We aim to look for protection against acute heart failure by molecular 
agents and delineate the pathways involved in recovery when we administer 
sphingolipids like sphingosine-1-phosphate which is a component of high density 
lipoprotein (HDL) cholesterol and a preconditioning agent 48 which is protective 
against ischemic-reperfusion injury.49 
Metabolism plays an imperative role in the progression of heart failure. Previous 
work by Booysen et al5o, describing the effects of adrenergic induced advanced 
dilation in rats by chronic isoproterenol administration discusses the effects of 
catecholamines on the left ventricle. Even though these effects were completely 
reversed after 4 months, it is an imperative finding for our validation of the model 
where we shall use adrenaline as one of the ways to induce AHF on the isolated rat 
hearts. The high speed generation and utilization of high energy phosphates is 
important in the maintenance of the heart's contractility. In our model of de novo 
AHF, we aim to irnpair the contractility by reducing its oxygen availability. Another 
study by Saupe et af1, on hypoperfusion induced contractile failure where they 
gradually reduced the oxygen availability of the hearts to examine the effect of 
hypo perfusion on production of ATP in these hearts. Another study by Elliott et af2 
showed that cardiac failure is mainly caused due to the changes in Pi and H+ and are 
secondary to hypoperfusion. In our model, we subject the hearts to a prolonged 
hypotensive phasE: to reduce the contractility. We are interested in examining the 
metabolism involved in acute heart failure and testing metabolic agents like glucose 
and insulin as therapy. 
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Section 3: Normal heart metabolisnl and 
proposed metabolism in an acutely 
failing heart 
Myocardial substrate utilization in the normal heart 
In a healthy adult heart, almost all ATP generation occurs by means of oxidative 
phosphorylation in the mitochondria.53 Glycolysis contributes the remainder of 
energy. In order to propose the metabolism in an acutely failing heart, it is imperative 
to understand the metabolism in a normal heart. T aegtmeyer refers to the human 
heart as a "metabolic omnivore" due to the variety of substrates used by the heart to 
generate ATP enerl~y.54 The heart uses carbohydrates, fatty acids, amino acids and 
even ketones to generate ATP. Fatty acids, however, are the major contributor to 
ATP generation as they generate almost 70% of the ATP needed by the heart. 55,56 
This ATP production by FFA utilizes more O2 molecules (see table) and is efficient in 
non-ischemic conditions. 
Table 1-3-1: ATP yield per molecule of different substrates. Glucose yields 38 ATP 
per molecule while fatty acids Palmitate and Oleate yield 129 and 144 respectively. 
However, glucose is more efficient in consumption of oxygen to produce ATP. Even 
though it is a small difference of 11 %, it is important in a failing or ischemic heart. 
ATP yield 
per molecule 
ATP yield per 
carbon atom 
ATP yield per 
oxygen atom taken 
up to (P/O ratio) 
Molecule Old" New Old NeW' Old New 
Glucose 38b 32': 6.3 5.2 3,17 2.58 
Lactate 18 14.75 6.0 4.9 3.00 2.46 
Pyruvate 15 12.25 5.0 4.1 3.00 2.50 
Palmitated 130 105 8.1 6.7 2.83 2.33 
(Copied from Opie LH, Heart Physiology: From Cell to Circultation) 29 
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CARBOHYDRATE METABOLISM 
Overview of Glycolysis 
In a normal adult heart, almost 60-90% of acetyl-coA is generated by the ~-oxidation 
of fatty acids while the remaining 10-40% comes from pyruvate oxidation which is 
derived from the glycolytic pathway and oxidation of lactate.53,57 Glucose is taken 
into the cell by the activation of glucose transporters GLUT1 and GLUT 4 (mostly 
GLUT 4 in the heart).58 The translocation of these transporters from the intra-cellular 
vesicles to the sarcolemma occurs in response to situations like ischemia, increased 
work or insulin stimulation. During exercise, the activity of AMP-activated protein 
kinase (AMPK) is also responsible for the translocation of GLUT 4 transporters to the 
sarcolemma. Glycolysis occurs in the cytosol and converts glucose to either pyruvate 
or lactate based on the availability of oxygen. Even though pyruvate is formed in 
both aerobic and anaerobic conditions, it is oxidized under aerobic conditions. It is 
converted to lactat!3 under anaerobic conditions.59 The first step in glycolysis is the 
phosphorylation of glucose to glucose 6-phosphate by hexokinase followed by action 
of phosphoglucose isomerase to fructose 6-phosphate which by 6-phosphofructo-1-
kinase forms frllctose1,6-biphosphate where ATP is converted to ADP. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is the first enzyme that 
generates NADH from nicotinamide adenine dinucleotide (NAD+) by oxidation and 
phosphorylation of glyceraldehyde phosphate.6o Downstream reactions in glycolysis 
produce 2 ATP and pyruvate from phosphoenol pyruvate in the aerobic conditions 
while in the absence of oxygen, NADH is reoxidized by lactate dehydrogenase, 
converting pyruvate to lactate. The pyruvate formed from glycolysis undergoes 
decarboxylation by the action of pyruvate dehydrogenase (PDH) to produce acetyl 
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Figure 1-3-1: Overview of Glycolysis. Acetyl-GoA is formed from pyruvate by the action of 
pyruvate dehydrogenase (PDH) which is the end product of Glycolysis. Two ATP and NADH 
are formed in the process. Acetyl-GoA subsequently enters the Krebs cycle. Gopied from 
Stanley Wet al. 53 
FATTY ACID METABOLISM 
Overview of myocardial fatty acid metabolism 
The rate of fatty acid uptake in the myocardium is defined by the concentration of 
non-esterified fatty acids in the plasma. These molecules are hydrophobic and are 
bound to proteins or covalently to co-enzyme A or carnitine . The transport of fatty 
acids through plasma is facilitated by being bound to albumin, very low density 
lipoproteins or triglycerides. 53 ,59,61 
Fatty acids enter the cell by passive diffusion or by means of a fatty acid translocase 
(FAT), which is a protein mediated transfer, or a fatty acid binding protein in the 
plasma membrane (FABPpm).62 CD36 is a FAT which is predominantly found in the 
heart. Once the fatty acids have diffused across the sarcolemma, they bind to FABP 
and are then esterified to fatty acyl-CoA by the enzyme fatty acyl-CoA synthase 
(FACS). The products of FACS i.e. long chain fatty acyl-CoA are either converted to 
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long chain fatty acylcarnitine by carnitinepalmitoyltransferase I (CPT1) or are 
esterified to triglycerides by glycerophosphate acyl transferase. Diglyceride 
acyltransferase (DGAT) catalyses the reaction between diacylglycerol and acyl-CoA 
forming triglycerides.63 CPT1 is responsible for the formation of long chain acyl 
carnitine from long chain acyl-CoA for transport between the inner and outer 
mitochondrial membranes. Once the transfer into the inner mitochondrial matrix is 
complete, carnitinepalmitoyltransferase II (CPT2) regenerates the long chain acyl­
CoA in the mitochondrial matrix. This long chain acyl-CoA undergoes j3-oxidation to 
generate acetyl-CoA, NADH and FADH2 which enter the Krebs cycle and electron 
transport chain to generate ATP and oxygen . 59.62.64 
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Figure 1-3-2: Overview of carbohydrate and fatty acid oxidation on the cell. FAT - Fatty acid 
translocase; CPT1 - camitinepalmitoyltransferase 1; A TP - Adenosine triphosphate; GLUT ­
Glucose transporters; TG - triglycerides; PDH - Pyruvate dehydrogenase; G6P - Glucose-6­
phosphate. (Copied from Stanley et al). 53 
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Proposed metabolic patterns in acute heart failure 
To sLlggest a common metabolic path in acute heart failure is like describing the 
understanding of the mythical creature, the Hydra. Just as severing one head of the 
Hydra does not kill the beast, similarly, one metabolic process in AHF cannot 
possibly describe all the metabolic processes in an acutely failing heart. I shall 
attempt to describe the proposed metabolism in the de novo setting of acute heart 
failure in this thesis. To understand the metabolic patterns, it is first important to 
describe the precipitating factors for acute heart failure and what effect they have on 
the metabolism of the failing heart. 
Acute heart failure manifests itself in multiple clinical presentations. Some of the 
common presenting factors are acute hypertension, volume overload, hypotension, 
atrial fibrillation, acute coronary syndromes, acute valvular heart disease, 
myocarditis, infections etc.65 Dar and Cowie performed a comparison of precipitating 
factors for acute heart failure in various registries in Europe and the United States.66 
They found that acute coronary syndromes (ACS) were the most common precipitant 
of AHF in all registries where roughly 40% of cases were caused by ACS. Almost 
40% of de novo AHF was caused by ACS while acute decompensation only 
contributed to around 20-25% of the cases, with ischemia being a common cause of 
cardiogenic shock which had the most in-hospital mortality rates. Other causes were 
atrial fibrillation and to a lesser extent infections (20%). In these registries, it is 
important to note that the cause of AHF was primarily ischemic and that the patients 
were aged 70-75 years, thus making AHF a "disease of the elderly". 
Para acute hypertension, defined as systolic pressure >150rnmHg on admission for 
the Helsinki-Zurich registry and >200mmHg for the New York registry was another 
precipitant of AHF in these patients but had very little in-hospital mortality.44,66 In the 
OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized 
Patients with Heart Failure; n=48,567) study by Gheorghiade et al,43 it was shown 
that patients with acute heart failure with reduced systolic pressure at admission 
showed higher in-hospital mortality. They also reported that the majority of patients 
in the study were aged 70-75 yrs which is consistent with the data from the various 
European studies.43 To understand the metabolism of AHF in these patients we need 
a thorough understanding of the precipitating factors and the effects they have at the 
cellular level. The important points such as mitochondrial energetics, neurohormonal 
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activation, utilization of fuels, production of reactive oxygen species (ROS) and 
calcium metabolism ill mitochondria need to be studied. 
Studies from the African continent done by Damasceno et af36 describe hypertension 
as the major cause of mortality in 1006 patients with acute heart failure. The study 
was performed in nine countries and the authors report that patients with acute heart 
failure had a mean age of 52 yrs and that there was no difference between the 
sexes. The authors report that the rate of readmission and death is similar to that 
seen in the European and American registries and is very high. 
Takotsubo cardiomyopathy is a subtype of acute heart failure characterized by 
rapid dilation of the left ventricle due to elevated catecholamines caused by an acute 
up-regulation of the sympathetic nervous system. This type of cardiomyopathy is 
also called stress Gardiomyopathy, with supra-physiological levels of circulating 
catecholamines (as high as 37 times the normal value) in these patients.46 They 
measured plasma catecholamines everyday from day 1 until day 9, finding that the 
catecholamines were elevated to the maximum on day 1 (37 times) with reduced 
concentrations by day 9, were still 10 times normal values. Almost all patients 
presented with chest pain with some patients requiring intra-aortic balloon pump on 
admission. 
Wittstein ef af1,45,46 suggest multiple hypothesis that could explain the relation 
between elevated catecholamines and myocyte injury in these patients. The first 
hypothesis suggests the calcium overload mediated by cyclic adenosine 
monophosphate (cAMP) causing a reduction in myocyte viability due to apoptosis. 
The second hypothesis considers Takotsubo cardiomyopathy due to epicardial 
spasms that lead to ischemia and in succession, myocardial stunning and 
microvascular dysfunction owing to abnormal perfusion. The third hypothesis deals 
with the idea of catecholamines causing endothelial stunning, leading to reduced 
coronary flow. 
Uchida ef aP hypothesised that microvessel apoptosis is a link between stress and 
Takotsubo cardiomyopathy, suggested that elevated catecholamines cause 
apoptosis in vascular endothelial cells via the catecholamine-J3 receptor-caspase 3 
and catecholamine-BCI2-caspase pathway. They conclude that stress-induced up-
regulation of catecholamines causes apoptosis of endothelial cells and microvessel 
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spasm, and that this In turn causes myocardial stunning, which leads to thinning of 
the ventricle walls.67 Mebazaa et afB showed the correlation between elevated blood 
glucose and 30 day mortality in patients with and without diabetes mellitus. They 
found that patients with high glucose had a lower survival rate (p<0.0001 vs. 
survivors at the end (If 30 days) both in patients with and without diabetes mellitus. 
The proposed hypothesis for this condition is that severe systemic stress, elevated 
blood glucose and an upregulation of sympathetic nervous system increase the 
concentration of Circulating free fatty acids which are deleterious to the failing 
myocardium. Hyperglycemia is also shown to induce apoptosis, alter calcium 
metabolism and cause remodeling in infarcted hearts.69 
Lessons learnt from clinical trials and proposed model of de novo AHF 
Clinical trials of AHF and Takotsubo cardiomyopathy (ischemic insult or an acute 
hypertension or hypotension due to haemorrhage triggers AHF or worsening of CHF) 
have shown that acute heart failure is caused by a heterogeneous combination of 
conditions, affecting both young and old people. Based on these hypothesis 
proposed by various authors, I think that acute heart failure almost always comprises 
of elevated catecholamines and the myocardial stunning leading to cell death seems 
like an area one should focus in order to improve the functional recovery of the heart 
and in turn, survival of patients. Elevated catecholamines suppress glucose uptake 
in the myocardium and may cause hyperglycemia if the insulin secretion is reduced. I 
propose that in an acutely failing heart, similar to a chronically failing heart with 
elevated catecholamines and elevated fatty acids, insulin secretion is reduced which 
causes reduced glucose uptake even if glucose is available. This kind of acute heart 
failure may be triggered due to an acute ischemic insult or hemorrhage causing 
hypotension and acute hypoperfusion of the tissue. I propose that hypoperfusion 
caused by metabolic abnormalities triggers apoptotic pathways and leads to cell 
death due to increased mitochondrial calcium and sodium content, formation of 
reactive oxygen species (ROS) and oxygen wastage associated with fatty acid 
uptake.7o Impaired mitochondrial efficiency causes decreased ATP production in 
conditions like ische'llia and chronic HF. Since most AHF is caused by 
decompensation of CHF19, I propose that in AHF too, there is a reduction in ATP 
production which may be improved by substituting the substrate utilization from 
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deleterious fatty acids to protective glycolysis and by administering insulin to 
facilitate glucose uptake?7,55,71 
Proposed model of de novo acute heart failure 
Based on the clinical presentations, metabolic studies and mitochondrial function, my 
model of de novo AHF is based on the following: 
• Reduced sys10lic pressure- which is associated with higher in-hospital 
mortality43 and is a rationale to use a hypoperfusion in our model. Opie 72 in 
1965 showed that left ventricular contraction could be calculated by 
multiplying heart rate and systolic pressure. I shall use this principle to reduce 
the left ventricular contractility by reducing the perfusion pressure. Studies by 
Bricknell and Opie73 used a similar model of underperfusion to simulate 
ischemia to examine the effects of substrates on metabolic changes and 
lactate dehydrogenase release in ischemia. 
• Elevated circulating catecholamines41 ,45,46-to inhibit glucose oxidation and 
promote fatty acid uptake. 
• Increased fatty acids and reduced glucose in perfusate:27,74 
This model uses a healthy isolated rat heart which is subjected to hypotension, 
reduced glucose, and elevated fatty acids in the perfusate and adrenaline to mimic 
the metabolic abnormalities in a failing heart. The hypotensive phase is achieved by 
reducing the perfusion pressure from 100 cm H20 to 20 cm H20 and fatty acids are 
introduced in the perfusate in this phase along with catecholamines while reducing 












PROMOTES HEART FAILURE 
Figure 1-3-3: Proposed substrate utilization in AHF (Copied from Opie LH, 2012) 
We propose that in de novo acute heart failure with no prior history of heart disease, 
the use of glucose as a fuel for mitochondrial oxidation instead of fatty acids could 
serve as a therapy for acute heart failure, as has been argued for chronic heart 
failure. 27 In addition, glycolysis is protective because it is more energy-efficient and 
hence causes less oxygen wastage, thereby protecting the myocardium.73.75.76 
MITOCHONDRIAL FUNCTION AND CELL DEATH IN ACUTE HEART FAILURE 
In a chronically failing heart as in an ischemic heart, mitochondrial dysfunction is 
closely related to worse outcomes in both animal models and patients. 77,78 We 
propose that in acute heart failure, similar stress situations like those in CHF and 
ischemia result in decreased ATP production and progressive worsening 
deterioration in mitochondrial integrity. Some of the stressors include impaired 
energetic, ROS production and excess calcium influx in the mitochondria. Rabuel C 
defines acute heart failure as a "reversible incapacity of the myocardium to provide a 
sufficient output for cellular metabolism". 79 This definition implies that there is an 
imbalance in energy utilization and energy production in an acutely failing heart 




In my model of de novo acute heart failure, I shall examine the mitochondrial 
respiration on a Clarke type electrode after an episode of AHF to see if treatment 
with glucose and insulin in perfusate improves mitochondrial function as opposed to 
fatty acids. 
Proposal:Mitochondria are involved in AHF 
Myocardial energetics: Acute heart failure is a rapid onset of, or change in, signs 
and symptoms of heart failure. 19 In CHF, mitochondrial energetic defects cause 
reduced creatine phosphate and ATP. The decrease in mitochondrial ATP 
production can be linked to altered substrate utilization, decrease of activity in the 
Krebs cycle enzymes or the enzymes of the electron transport chain. We propose 
that these defects in a chronically failing heart, when accelerated due to events like 
arrhythmias or an acute myocardial infarction, cause rapid deterioration of 
mitochondrial integrity and reduction in the production of myocardial high energy 
phosphates. 
Reactive oxygen species (ROS) and calcium overload 
Mitochondria during acute coronary syndromes such as ischemia generate high 
amounts of reactive oxygen species80 and cause oxidative stress, which impair the 
electron transport chain and generate even more ROS.29 This causes damage to the 
mitochondrial membrane and may lead to cell death by opening of the mitochondrial 
permeability transition pore (mPTp).81 Calcium modulation in a cell is also closely 
monitored by the mitochondria. They maintain homeostasis in the cell by maintaining 
the levels of calcium to prevent any changes in membrane potential. A rise in 
cytosolic calcium also causes a rise in the mitochondrial calcium content, leading to 
the opening of the mPTP, which leads to cell death. 
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and elevated FAO 

APOPTOSIS 
Figure 1-3-4: Proposed mitochondrial function in an acutely failing heart: A TP production is 
reduced due to utilization of free fatty acids (FFA) as substrates, hence reducing adenosine 
triphosphate (A TP) production, caspase activation leads to apoptosis and increase in free 
radicals causing oxidative stress. (Figure adapted from Rabuel C)79 
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Section 4: Sphingosine-l-phosphate and 
acute heart failure 
Introduction 
"It is a riddle wrapped in a mystery inside an enigma" is how Karliner describes the 
sphingolipid sphingosine-1-phosphate (S1 p).82In 1884, "Father of Neurochemistry", 
JLW.Thudichum named the sphingolipids as such due to their mysterious chemical 
backbone and their inscrutable properties. The riddle of sphingolipids and their 
actions has now, however, been somewhat simplified, thanks to a lot of work in the 
world of sphingolipid signalling. S1 P is now known to be involved in various cellular 
processes in the cardiovascular system, immune system and nervous system. S1 P 
shows cardioprotective effects by decreasing infarct size after ischemic-reperfusion 
injury has been associated with cell proliferation, differentiation, permeability of 








Figure 1-4-1: Chemical structure af sphingasine-1-phasphate 
Sphingomyelin produces many lipid components in the sphingomyelinase pathway, 
one of them being ceramide. Ceramide is then deacylated to sphingosine which is 
then phosphorylated by sphingosine kinase 1 or sphingosine kinase 2 to form 
sphingosine-1-phosphate. Ceramide and S1 P have opposite effects in the cel1.85 
While S1 P is protective and non-apoptotic, cerarnide is considered to be pro-
apoptotic. The homeostasis between the two decides the fate of the cells. The main 
source of S1 P in plasma is the erythrocytes, while minor sources include platelets 
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and endothelial cells. The concentration of S1 P in human plasma is between 200­
1000 nM.86 Despite being present in such high concentrations in the plasma, a very 
low concentration of free S1 P is available for activity, mostly because S1 P is bound 
to high density lipoprotein (HDL) cholesterol molecules and albumin and, to some 
extent, by low density lipoprotein (LDL) cholesterol and very low density lipoprotein 
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Palmitaldehyde Phosphoethanolamine 
Figure 1-4-2: The synthesis of S1P from sphingomyelin. The reaction from ceramide to S1P 
is reversible in order to maintain cellular balance of the two opposing molecules. S1 P lyase 
breaks down S1P into palmitaldehyde and phosphoethanolamine and is not a reversible step 
in the cascade. (Adapted from Kennedy el al)85 
S 1 P has two modes of action: both by extracellular receptors and as an intracellular 
messenger. S1 P binds to a group of cellular receptors called the G-protein coupled 
receptors or GPCR's which were discovered in the early 1990's and originally named 
as endothelial differentiation gene receptors.17,87 S1 P binds to its receptors and 
initiates a cascade of metabolic processes in various systems. Five receptors for 
S1 P have been identified in the human body to date, namely S1 PR1-5 . These 
receptors are found in the cardiovascular system, nervous system and the immune 
system as well as the kidneys. 
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S1P is an important intracellular messenger 
S 1 P as an intracellular agent influences the regulation of calcium in the ce1l37,89 and 
suppresses apoptosis.83 Despite the fact that the mechanisms and intracellular 
targets of S1 P remain unknown, Spiegel and Kolesnick state in their review that in 
cells like yeast which lack the GPCR's, phosphorylated sphingolipids modulate 
activities like cell growth and survival. 83 In plant cells, which also lack S1 Preceptors, 
intracellular S1 P is responsible for calcium homeostasis and ion channels. 83,9o Above 
all, studies by van Koppen show that microinjection of S1 P into mammalian cells 
induces calcium activity and cell proliferation .83 ,91 S 1 P has a wide range of effects 
which are dependent on the signaling in which it is involved. However, for the 
interest of this thesis, I shall be focusing on the S1 P receptors in the cardiovascular 
system only. 
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Figure 1-4-3: The different receptors of S1P in the body that regulate physiological 
processes, S1P1- S1P receptor 1; S1P2- S1P receptor 2; S1P3- S1P receptor 3. 17S1PR1-3 
have been identified in the heart so far and the physiological responses of S 1 P binding to 
each of the receptors is different. While S1P1 is mostly observed in endothelial cells, S1P2 
is expressed in vascular smooth muscle cells which also express the S1P3 receptor, 
51 P and cardiovascular diseases 
Sphingosine 1 phosphate is formed by the phosphorylation of sphingosine in the 
presence of sphingosine kinase (SphK) (Refer to figure in Introduction section 
above). SphK has two isoforms: Sphingosine kinase 1 (SphK1) and 
Sphingosinekinase 2 (SphK2). SphK1 levels are elevated in ischemic 
preconditioning (IPC), which is a process where short cycles of ischemia and 
reperfusion are administered before the actual ischemic insult. 92 IPC is 
cardioprotective and reduces infarct size. SphK1 is activated during IPC, promoting 
the formation of S1 P, which in turn is cardioprotective and reduces infarct size. 
Lecour et al were the first to show protection by S1 P in isolated rat hearts84 and 
these results were confirmed in the isolated cardiomyocytes by Karliner et a/.93 In 
other studies using isolated cardiomyocytes, Zhang94 and Vessey95 showed that 
cardioprotection by S1 P was equivalent to that of IPC (cycles of hypoxia and re-
oxygenation, mimicking ischemia-reperfusion cycles) with a cell survival rate of 
around 93% compared to controls that were exposed to only hypoxia-reoxygenation 
and had a mortality rate of around 40%. S1 P exerts its effects by binding to its 
GPCRs. There are 3 receptors in the heart and they modulate different functions, 
despite being expressed in the same cells. Endothelial cells mostly express the 
S1 P1 receptor and to some extent S1 P3 as well. On the other hand, S1 P2 is found 
in vascular smooth muscle cells.17 The vasoconstrictive effects of S1 P were 
abolished by the addition of JTE013, an antagonist of S1 P2. In the cerebral artery, 
S1 P3 is responsible for vasoconstriction, demonstrating the distribution of S'I P 
receptors and their heterogeneity. The effects of S 1 P are also dependent on the 
concentration in the plasma. In rat studies, a high concentration (>30mM) of S1P 
caused vasoconstriction while lower levels of plasma S1 P (0.1-0AmM) caused 
relaxation. The vasodilative effects of S1 P are mediated through S1 P1 and S1 P3 
and almost always require the activation of endothelial nitric oxide synthase (eNOS) 
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leading to the release of endothelial nitric oxide (NO).85 In studies by Sugiyama et al 
on the canine sinus node, S1 P increased the sinoatrial rate, while the ventricular 
blood flow and contraction were reduced.96 Their study also revealed that S1 P had 
no effect on the aden'}flate cyclase activity suggesting that S1 P might be activating 
cyclic AMP via an indirect pathway.96 The regulation of heart rate and sinus rhythm 
has been attributed to the S'I P3 receptor as shown by Sanna et al.97 
S1 P and heart failure 
Very few studies have focused on the effects of S1 P in the failing heart. In a study 
published by Knapp et af8 in 2012, they attempted to measure the plasma 
concentrations of major sphingolipids in patients with chronic heart failure and 
healthy controls and found that there was no difference in plasma levels of S1 P and 
ceramide between the two groups. However, they report that the levels of free 
sphingosine and sphinganine were reduced by 25% and 27% respectively in patients 
with systolic failure.98 
Heart failure is associated with elevated fatty acid metabolism and reduction of 
protective glycolysis. In type 2 diabetes, ceramide concentrations in blood, muscle, 
adipose tissue and liver are increased, which is thought to be linked to progression 
of insulin resistance. Studies using pancreatic J3 cells showed a metabolic role of 
S'I P. Exposure to high glucose stimulates sphingosine kinase (SphK) activity in the J3 
cells, and leads to the secretion of insulin. This activation of SphK caused an 
increase in the plasma S1 P concentration and this was abolished when SphK2 was 
knocked out. This sU~lgests that the glucose-stimulated insulin secretion in the 
pancreas is mediated by SphK2. 99 This may be very important as a therapy in heart 
failure as the substrate utilization is altered with the heart utilizing fatty acids to 
generate ATP while wasting oxygen in the process. An up-regulation of insulin would 
cause the uptake of glucose, thus activating protective glycolysis and potentially 
salvaging the failing myocardium, suggesting a role of S1 P in cardiac metabolism. 
Mechanisms involved in protection with S1 P in heart failure 
To delineate the pathways by which S1 P exerts its cardioprotective effects is a 
challenge because S1P acts as an intracellular Signaling molecule and also acts via 
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binding to its receptors to induce a variety of proliferative outcomes in the cells. 
Recently, S1 P as an intracellular molecule has been shown to be transported my 
means of cystic fibrosis transmembrane conductance regulation (CFTR) in a mouse 
model of heart failure. The same study showed that CFTR expression is abolished in 
heart failure and that this is caused by elevated levels of TNFa. 100,101 Studies by 
Somers et a/102 show that S1 P-induced cardioprotection after an ischemic-
reperfusion injury is mediated by the activation of two powerful pro-survival 
pathways: namely Reperfusion Injury Salvage Kinase (RISK) which involves the 
activation of Aktlextra cellular signal regulated kinases (Erk)103 and Survivor 
Activating Factor Enhancement (SAFE) pathway which requires the activation of 
tumor necrosis factor a (TNFa)/ signal transducer and activator of transcription 3 
(ST AT3) molecules. STAT3 requires translocation to either the nucleus or the 
mitochondria 104 post-phosphorylation. This transfer of phosphorylated ST AT3 to the 
mitochondria is mediated by S1 P in a mouse model of ischemic-reperfusion injury. 
However, the protection by S1 P was abolished by the inhibitors of both RISK and 
SAFE pathways suggesting that the cardioprotective effects of S1 P require the 
activation of both pathways and that S 1 P acts as a common ladder in the unification 
of these prosurvival pathways.102 While the SA FE pathway is activated by a host of 
factors and molecules like insulin, opioids, HDL, melatonin, resveratrol and ischemic 
pre- and post-conditioning,104 all these examine the SAFE pathway in the scenario of 
ischemic-reperfusion injury. There are no studies examining the effect of S1 P in 
acute heart failure (AHF) or the involvement of prosurvival molecular pathways that 
might be active durirm AHF.104 As Douglas Mann says, "One of the qualities of 
important research is that it frequently stimulates more questions than can be 
answered in a single :study".105 All these studies showing S1P promoting survival 
have sparked our intemst in examining the effect of S1P in our model of AHF and we 
hope to delineate the molecular pathways involved if S 1 P is found to be protective. 
One of the hypotheses we propose is that since S1 P increases the secretion of 
insulin, it could activate the SAFE pathway and lead to better recovery after an 
episode of AH F. 
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Fig 1-4-4:Cardioprotective RISK and SAFE pathways89(RISK- Reperfusion injury salvage 
kinase; GPCR- G protein coupled receptor; Erk- extra cellular signal regulated kinases; 
PI3K- phosphatidylinositol-3-0H kinase, GSK3{3- glycogen synthase kinase 3 {3; S1 P­
sphingosine-1-phosphate; S1PR1IR3- S1P receptors 1 and 3; SAFE- survivor activating 
factor enhancement; TNFa- tumor necrosis factor a; JAK- Janus kinase; STAT3- signal 
transducer and activator of transcription 3; mPTP- mitochondrial permeability transition pore) 
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Chapter 2 
AIM and HYPOTHESIS 
AIM 
The lack of knowledge regarding the metabolism and effects of novel 
pharmacological agents in recovery against de novo acute heart failure is a possible 
major drawback in development of new treatments and therapies against AHF. 
Hence, the aim of this thesis is to establish a model of de novo acute heart failure 
using an isolated rat heart model on the Langendorff retrograde perfusion system 
and test pharmacological and metabolic agents for recovery and delineate the 
pathways involved in protection. 
HYPOTHESIS 
1) Using our newly established model of de novo AHF, we hypothesize that the 
addition of molecular agent sphingosine-1-phosphate (S1 P) improves the 
functional recovery after an episode of de novo acute heart failure and that 
the protection is mediated by the Survivor Activating Factor Enhancement 
(SAFE) pathway 
2) We further hypothesize that glucose and insulin improve functional recovery 
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Figure 2·1: Hypothesis tnat treatment with metabolic and pharmacological agents improves 





To establish and validate a model of de novo acute heart failure and test metabolic 
and pharmacological a~Jents for recovery, we used the following methods; which will 
be described in details here: 
• Isolated rat heart Langendorff perfusion to determine the functional recovery 
of hearts 
• Western blotting to determine the protein concentration for cell death and 
molecular mechanism determination 
• Mitochondrial respiration measurement using a Clarke-type electrode 
Isolated rat heart perfusions 
All experiments were conducted in male Long Evans rats weighing 250-320 g. 
The rats were anaesthetised using sodium pentabarbitone (60mg/kg ip) in a syringe 
that was flushed with heparin to prevent blood clotting. The lack of pedal reflex 
tested the level of anaesthesia and once anaesthesia was established, the skin was 
incised at the xyphoid-sternum followed by the incision of the ribs to open the 
thoracic cavity. The ht3art was then removed rapidly and was transferred to a 
Petridish containing ice cold Krebs-Henseleit buffer. 106 The buffer consisted of 
sodium chloride (NaCI) (118.5mM, Sigma), sodium hydrogen carbonate 
(NaHC03)(25mM, Merck), potassium chloride (KCI) (4.7mM, Sigma), magnesium 
sulphatehepta-hydrate (MgS04 . 7H20) (1.2mM, Merck), potassium di-hydrogen 
phosphate (KH2P04)(1.2mM, Sigma), glucose (11.1mM, Merck) and calcium chloride 
dihydrate (CaCI2) (1.3mM, Sigma). The aorta was cannulated and the heart was 
mounted on the Langendorff retrograde perfusion system. A 2-0 silk ligature was 
used to tie the heart on the cannula. A pressure transducer (AD Instruments) 
attached to a balloon was inserted into the left ventricle of the heart and the 
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pulmonary artery was snipped to release the Krebs-Henseleit buffer from the right 
ventricle. The balloon was inflated while inside the LV and the heart was to beat 
against the inflated balloon. The inflation of balloon was standardized when the LV 
developed pressure was maintained between 80-120mmHg in all hearts during the 
stabilization period. The mechanical beating of the heart was converted to an 
electrical signal which was subsequently read on the computer. Standard baseline 
parameters were set for every heart which were: HR between 240-420 BPM. The 
diastolic pressure was maintained below 12 mmHg. The acceptable baseline LV 
developed pressure was more than 80 mmHg while the coronary flow of the heart 
was between 8-12 ml per minute. The hearts were maintained at 37°C. The hearts 
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Stabilizat ion : Recovery 
Figure 3-1: Basic flow diagram of our Langendorf( retrograde perfusion system to induce 
acute heart fai/ure on an isolated rat heart. 
The three phases i.e. Stabilization, Acute Heart Failure and Recovery. Each phase 
can be independently activated by switching the other reservoirs off at the stop-cock. 
The Stabilization phase and recovery phase were perfused at a 100 cm H20 while 
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the AHF phase had Ct perfusion pressure of 20 cm H20. A balloon connected on one 
end to a pressure transducer was inserted into the left ventricle which converted the 
mechanical signal from the heart to an electrical signal. 
The model consisted of three phases: 
Phase 1: Stabilization: which took place over 30 min at 100 cm H20 perfusion 
pressure with glucose (11.1 mmol/L) as the sole substrate in the perfusion buffer. The 
basal functional parameters were achieved in this phase. The accepted baseline 
parameters are described in the table below. Hearts were maintained throughout at 
37°C. The purpose of this phase was to wash any metabolites and achieve the 
threshold parameters for heart rate, left ventricular developed pressure, diastolic 
pressure and coronary flow. Hearts that did not meet the parameters at the end of 30 
min were excluded from the study. 
Exclusion criteria for isolated perfused hearts 
Parameter 
Heart rate (HR) 
Values 
240-420 beats per minute (BPM) 
I 
I 
tricular end diastolic pressure (L VEDP) Left ven 0-12 mmHg 
.---­.. 
Left v entricular developed pressure (L VDP) 
.-~.--~~.. 




Phase 2: Acute heart failure phase: This phase took place over 35 min where the 
perfusion pressure was dropped to 20 cm H20 and the glucose concentration was 
reduced to 2.5 mmol/L with addition of fatty acids (1.3 rnmol/L) in the perfusate. 
Previously, Bricknell and Opie73 established a model of low pressure global 
ischaemia with residual oxygen uptake to study the effects of substrates on tissue 
metabolism and measurement of lactate dehydrogenase and arrhythmias during 
reperfusion. They reduced the perfusion pressure from 100 cm H20 to 20 cm H20 to 
simulate a model of global ischaemia. We used the similar principle of reducing 
perfusion pressure to mimic the hypotension associated in patients with acute heart 
failure. The change in substrate concentration was made in order to reduce the 
uptake of glucose by the isolated heart. In their experiments, Hamilton and 
S9 
Saggerson56 found that in a dose response to measure the production of malonyl 
CoA concentration in myocytes, 2.5mmol/L of glucose significantly reduced the 
concentration of malonyl CoA when compared to physiological 5mM. Malonyl CoA 56 
is formed by the carboxylation of acetyl CoA by acetyl CoA carboxylase (ACC). 
Malonyl CoA is responsible for the inhibition of the activity of carnitine 
palmitoyltransferase-1 (CPT-1) which regulates the uptake of fatty acids by 
transferring the long chain fatty acyl CoA through the membranes of mitochondria.62 
Hence, we decided to reduce the concentration of glucose in our model of acute 
heart failure to promote the upregulation of fatty acids. Fatty acids were introduced in 
this phase of the experiment. We used 1.3mmollL of fatty acids bound to 1.4molll 
bovine serum albumin (BSA). Aasum and Larsen 107 in 1997 showed impaired 
ventricular function and calcium homeostasis when hearts were perfused with 1.2 
mM Palmitate and ~llucose. We aimed to induce acute failure in the isolated rat 
hearts; hence, we used higher concentration of fatty acids. 
Phase 3: Recovery phase: This phase lasted 30 min where perfusion pressure was 
restored back to 100 cm H20 but fatty acid and glucose concentration in the 
perfusate was unaltered from previous phase. We aimed to observe the effects of 
low glucose and high circulating fatty acids despite the improvement in perfusion 
pressure, thus mimicking the recovery phase in patients with hypotensive de novo 
acute heart failure or patients with hypotensive Takotsubo cardiomyopathy. 
WESTERN BL01"TING 
Lowry protein determination 
51J1 (in duplicates) of aliquots of each sample were added to 9951J1 distilled water 
which was followed by addition of 1ml Solution A (Na2C02 (20%) and CuS04.5H20 
(0.2 g) + dipotassium tartarate (0.4 g) in 100 ml were mixed 1:1 to make a final 
volume of 200 ml CTC reagent. To this, 200 ml of 10% SDS and 200 ml of 0.1 M 
NaOH were added. The total volume of Solution A was 600 ml. Samples were 
immediately vortexed and incubated for 10 min at room temperature. Following that, 
500IJI Folin's reagent (Merck); diluted 1:6 (Solution B) was added while vortexing 
because the color complex forms immediately. The samples were then incubated for 
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30 min and thereafter read at 750 nm on a Varian 120 dual spectrophotometer. BSA 
was used to construet a standard curve from 5-200 I-Ig/ml and was read in the same 
way as the samples. 
Bradford protein determination 
Protein determination was done using a Bradford assay. loa The Bradford reagent 
was diluted to a 1 x working solution with distilled water. In an Eppendorf, 51-11 of 
protein sample and 951-11 of distilled water were mixed, and 9001-11 of the Bradford 
reagent was added. After mixing, 2001-11 of each sample was loaded onto a 
microplate for the absorbance to be determined .. The components were protected 
from light as far as oossible for the duration of the assay to prolong the stability of 
the working solution, BSA standards were added to separate wells and mixed, these 
served to construct a standard curve to determine the protein concentration. Protein 
extracts were added to separate wells (10pl per well) and mixed. Absorbance was 
measured at 595nm using a microplate reader (GloMax, Promega, Fitchburg, WI 
53711) and protein concentration was determined from the standard curve. All 
samples were assayed in duplicate. 
Table 3-1: Composition of buffers for protein extraction 
Hypotonic Buffer Hypertonic Buffer 
1M HEPES pH 7.9 1ml 
O.lM EDTA 100ul 
1MDTT 100ul 
O.lM EGTA lOOul 
O.1M PMSF 1ml 
1M KCI 1ml 














Protein extraction: Cytosolic and Nuclear 
400ul of hypotonic buffer was added per tube. Crushed hearts were added in 
Eppendorff tubes and left on ice for lysis. 25 ul of 10% NP-40 (16x dilution of 
Nonident P40 IIGEPAL 100% with dH20) was added to this and vortexed for 30 sec 
followed by incubation on ice for 5 min. The sample was vortexed again and then 
centrifuged for 3 min at 13200 RPM at 4°C. The resulting supernatant was collected 
which was the cytoplasmic fraction. The pellet was washed with 2001-11 hypotonic 
buffer and vortexed again followed by centrifugation at 4°C for 3 min at 13200RPM. 
Extraction of the nuclear protein from the sample was carried out by, the discarding 
the supernatant and resuspending the pellet in 100ul of hypertonic buffer. This was 
then vortexed and left on ice for lysis for 20 min. After the lysis step, the sample was 
centrifuged for 7.5 min at 13200RPM at 4°C. The resultant supernatant contained 
the nuclear fraction. 
Proteins were adjusted to the same concentration; diluted 1:1 with low ionizing buffer 
or Lamelli buffer before preparing gels. 
Table 3-2: Components for gels 
lower Gel 2 gels 4 gels Upper gel 2 gels 4 gels 
dH20 9.Sml 19.Gml 7.5ml 15ml 
1.sM Tris HCI pH S.S 5ml 10ml O.SM Tris HCI pH 6.S 3ml 6ml 
20%SDS lOOul 200ul GOul 120ul 
Acrylamide (40% Bis) 5ml 10ml 1.5ml 3ml 
10%APS 100ul 200ul SOul 160ul 
Bromophenol blue to colour 
TEMED (ADD BEFORE POURING) 40ul SOul 40ul SOul 
To run the gels, the glass plates and combs were wiped clean with ethanol. The 
plates were set up and checked to avoid any leaks. The lower gel was poured into 
the space between olates and was allowed to set. This was followed by pouring the 
upper gel and the combs for wells were inserted. Approximately after 15 min when 
the gel was set, the assembly was removed and inserted into the running chamber 
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and the chamber was filled with running buffer. The combs were removed carefully 
and the wells were flushed to remove any air bubbles. The samples were denatured 
by suspending the Eppendorff tubes in boiling water for 5 min. The samples were 
then vortexed before loading. 
3-10 1.11 of protein ladder was added in the first lane and the samples in the 
subsequent lanes. Hunning buffer was added to the outer compartment of the gel 
tray to the same level as the inner compartment and the gels were run at 100V for 
-2.5 hours or until the gel front reached the end of the gel. The transfer step in the 
protocol was prepared in this time. 
To transfer the proteins from the gel to the membrane, PVDF membrane was cut to 
size of the gel and washed in methanol for 5 min followed by a wash with distilled 
H20 for 2 min. It was then left in cold transfer buffer. To set up the sandwich, ice cold 
transfer buffer was poured into dishes and the sandwich was prepared as illustrated. 
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Figure 3-2: Composition of layers for transfer of gels 
Once the gel was run, the lower gel was cut and placed onto the membrane and 
extreme care was taken to avoid air bubbles between membrane and gel. The 
cassette was placed in the holder and transfer process took place at 0.02A overnight 
or 0.2A for 2 hours at 4°C.Foliowing transfer, the membrane was removed and was 
fixed in methanol for 30s and then air dried completely. 
The membrane was labeled, washed with Ponceau, rinsed with dist H20and placed 
between cellulose acetate film and scanned. It was then washed with TBS-T once by 
hand followed by 3 X 5 min washes. This was then followed by blocking with milk 
powder in TBS-T for 2 hours at room temperature. This step was followed by 3 more 
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washes with TBS-T for 5 min. Membrane was exposed to primary antibody (1 :3000-
1 :10,000 in TBS-T with 5% milk powder) overnight at 4°C. 
The following day, membrane was washed 3x% with TBS-T and exposed to 
secondary antibody (1 :3000 - 1 :5000 in TBS-T) for 2 hours at room temperature. 
This was followed by more washing (3 X 5 min with TBS-T) and developed with ECl 
reagent (5 x 5min exposures with no light followed by 1 x 2sec white light exposure) 
for visualization. 
MITOCHONDRIAL RESPIRATION MEASUREMENT 
Failing hearts are less energy efficient in utilizing the substrates for generation of 
ATP, the currency of energy for the cell. Five groups were studied: baseline hearts 
with no heart failure, control, S1 P, Insulin and S1 P + Insulin with the drugs having 
administered in the recovery phase. Also, the recovery phase was reduced to 7' in 
order to obtain as many viable mitochondria as possible. The substrates in the 
recovery phase were glucose (11.1 mmol/l) and FFA (1.3mmol/l) for all hearts 
The parameters measured were State2, State3, State4 respiration and respiratory 
control index (RCI). The mitochondrial protein was measured using a Qubit assay to 
normalize the values for all mitochondrial proteins. 
Buffers for mitochondrial extraction and measurement of respiration on the 
oxygraph 
Isolation medium: The isolation medium to mince the heart and homogenize the 
heart consisted of 0.18M KCI, 0.001 M Ethylenediaminetetraacetic acid (EDTA) and 
the pH was set to 7.4 using Tris. 
Incubation buffer: The incubation buffer was freshly made for every experiment. It 
consisted of 1.25 M Sucrose, 1 OOmM Tris-HCI, 85mM K2HP04 
Glutamate (50mM) was used as substratefor mitochondrial respiration. 
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Mitochondrial Isolation Procedure 
The buffers were prepared as per instructions, the hearts were removed from the 
perfusion apparatus and immediately placed in Petri dishes containing ice cold 
isolation buffer. The heart was cut into very small pieces using small scissors. Once 
this was done, the hearts in the isolation buffer were transferred into a Teflon 
homogenizer. They were homogenized till the hearts were liquidized. This 
homogenate was then transferred into centrifuge tubes and spun for 10 min at 4°C at 
2390 RPM. The resultant supernatant was transferred to another clean centrifuge 
tube and the pellet was discarded. This supernatant was then spun again at 4500 
RPM for 10 min at 4°C. After centrifugation, the supernatant was discarded this time 
and the mitochondria containing pellet was resuspended in fresh incubation buffer. 
This mixture was then transferred into a fresh Eppendorff'9 tube. 
Mitochondrial respiration measurement procedure 
The mitochondrial respiration studies took place on an Oxygraph (Oxytherm, 
Hansatech). The oxygraph contains a 1 ml chamber and has a S1 Clark type 
polarogenic oxygen .3lectrode disc. This forms the floor of the electrode chamber. 
The chamber contained 3161-11 of incubation buffer. A baseline reading was taken for 
a minute to verify tht3 stability of the calibration. Once that had been achieved, 20 1-11 
of 50mM Glutamate was added as substrate in the chamber. 50 1-11 mitochondria were 
added to the chamber and respiration was measured in presence of glutamate. This 
represents State2 respiration in absence of ADP. Once this was stabilized, 14 1-11 of 
10mM ADP was added to the chamber and the respiration was measured where 
ADP was rapidly taken up by the mitochondria to produce ATP. This was State3 
respiration in the protocol. This phase was followed by State4 respiration where all 
ADP has been converted to ATP and the respiration is steady again. The RCI was 
calculated as a ratic of values of State3/State4. Respiratory control index (RCI) is a 
measure of viability of the mitochondrial population and a higher RCI indicated 
greater amounts of respiring mitochondria. 
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Chapter 4 
VALIDATION OF AN EX-VIVO 
MODEL OF DE NOVO ACUTE 
HEART FAILURE 
INTRODUCTION 
Acute heart failure (AHF) is associated high in-hospital mortality in patients 
presenting with low systolic blood pressures and adequate therapies are needed to 
improve the patients' health,43 Most AHF results from acute decompensation of CHF 
where, a chronically failing heart deteriorates rapidly. The origins and 
pathophysiologies are multiple and our understanding of the disease mechanism 
remains very poor in part due to the paucity of basic research in the field. 19,39,109 The 
lack of an experimental animal model exploring the mechanisms of de novo AHF 
may explain the lack of knowledge and lack of efficient therapies. We therefore 
aimed to develop a simple and reproducible model to induce de novo AHF using an 
isolated rat heart model that we developed.49 This model is to our knowledge, the 
first small animal model of AHF. Our model will hopefully contribute to better 
understand the pathophysiology of the disease and its underlying mechanisms and 
may serve as a tool to explore potential therapeutic targets for the disease. 
Our model of de novo AHF mimics the clinical conditions of "cardiogenic shock" 
where the perfusion pressure that governs the external work in the perfused rat heart 
is abruptly reduced, as would happen when massive myocardial infarction in humans 
results in decreased myocardial contractility and hypotension (see table).Our model 
uses simulated hypotension with reductions in heart rate and substrates provided in 
the perfusate. The isolated heart model has both similarities to and dissirnilarities 
from human clinical AHF with low blood pressure as inpatients with Takotsubo 
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'stress' cardiomyopathl6,110 who may have AHF with lower systolic pressures (50­
104 mmHg)43without any prior heart disease. Therefore, we tested the effects of high 
circulating catecholamines in our model of the acutely failing underperfused heart,73 
We also induced AHF by cardiac pacing,111 or by the addition of adrenaline in 
increasing concentrations and we induced AHF by altering calcium and glucose 
concentrations in the perfusate. 
Table 4-1: Comparison and differences between human AHF and our model 
Conditions Human AHF Our model of AHF 
Onset 
Mostly acute-on-chronic (80%) 




Almost 25% in Europe and 
USA; 45% in Africa36 
Future work 
Hypotension 
10% of all patients in USA and 
Europe39.43; Reduced systolic 
pressure associated with 
higher mortalitl3; Known in 
patients with Takotsubo 
cardiomyopathy 46 
Reduction of perfusion 
pressure to induce 
hypotension 
Catecholamines 
No data available, however, in 
stress situations like AHF, 
catecholamines will be 
elevated; In Takotsubo 
cardiomyopathy, supra-
physiological levels of 
circulating catecholamines41 ,46 
High levels of adrenaline 
added in the AHF phase of 
the protocol 
Substrates 
No data available in AHF 
patients; elevated 
catecholamines will lead to up-
regulation of FFA oxidation 
Added high free fatty acids 
in perfusate; glucose 
concentration reduced 
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• Hvperadrenergic stimulus to induce acute heart failure 
Patients with Takotsubo cardiomyopathy and acute heart failure, have supra-
physiologial levels of circulating catecholamines.46 We therefore developed our 
model of acute HF in which we gave adrenaline in the acutely failing heart coupled 
with low glucose and high FFA in the perfusate. To validate an optimal model of 
de novo AHF, we used three concentrations of adrenaline for our study: 10.6, 10.8 
and 10.10 M to ilduce AHF and monitor recovery. Previous work from our 
laboratory by Horak and Opie7o showed that adrenaline at 10·8M caused 
decreased efficiency of pressure work or "oxygen wastage" in catecholamine-
induced myocardial injury. We tested three concentrations. 
• Glucose alteration in perfusate 
Glucose utilization for ATP production is reduced in a failing heart owing to the 
elevated adrenergic stimulus which promotes preferential fatty acid oxidation27 
11.1 mmoliL glucose is the standard concentration in isolated heart protocols while 
physiological glucose concentration is 5mmollL. Previous studies on cardiac 
myocytes to investigate the changes in malonyl-CoA in response to glucose 
alterations have used the concentration of 2.5mmol/L. 56 However, this 
concentration of glucose has never been used in an isolated heart to induce de 
novo AHF. Hence we used two concentrations, 5 and 2.5mmol/L to examine the 
effects of each in the AHF and recovery phase. The fatty acids in the buffer were 
maintained at 1.3mmol/L in AHF and recovery phases. 
• Calcium modulation as a model of acute heart failure 
Calcium Signaling plays an important role in the contraction of the heart. 
Contractility is compromised in a failing heart (Opie, LH, Heart Physiology; 4th 
edition). Calcium is shuttled in and out of the myocyte during every contraction-
relaxation cycle. Altered calcium concentration in the heart is linked to risk of 
chronic heart failure, due to arrhythmias.112.113 Hence we hypothesized that acute 
alteration of calcium concentration in the perfusate from 1.3 to 2.5mmol/L would 
promote contractile dysfunction, leading to de novo acute heart failure. The 
experiment was done in 3 phases: stabilization, AHF phase and recovery phase. 
The composition of the buffer for stabilization phase was same as described 
above. In the AHF and recovery phases, however, the calcium concentration was 
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increased to 2.5mrnol/L. The glucose concentration and fatty acid concentrations 
were 2.5 and 1.3mmol/L respectively. This is to force the heart to utilize more fatty 
acids over glucose and to promote heart failure. The perfusion pressure during the 
acute heart failure phase was20cm H20 while the recovery phase was at 100 cm 
H20. Temperature was maintained at 37°C throughout the protocol. 
• Pacing to induce acute heart failure 
Pacing has been used extensively as a model of chronic heart failure in canine 
studies by Stanley et al. 111 Pacing in dogs for 28 days caused LV hemodynamic 
alterations and dilation in their studies. We decided to pace rat hearts on our 
Langendorff retrograde perfusion system to examine whether acute pacing would 
cause acute heart failure. We examined 2 pacing speeds; 300 BPM and 150 BPM. 
The hearts were paced in the acute heart failure phase of the protocol for 35' in the 
presence of 1.3mmol/L FFA and 2.5mmol/L of glucose in the perfusate. 
HYPOTHESIS 
We hypothesize that these different alterations used individually or in combination in 
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Figure 4-1: Hypothesis diagram to validate models to induce AHF 
MATERIALS AND METHODS 
Animals 
Adult Long Evans rats were used for the experiments in accordance with the Guide 
for the Care and Use of Laboratory Animals. The ethics committee of the University 
of Cape Town medical school approved all experiments (project no 011/038). The 
rats were housed in the animal unit at University of Cape Town, medical campus and 
had free access to food and water. 
Isolated rat heart perfusions 
The heart perfusions were done as described in the methods sections in Chapter 2 
of this thesis. 
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Figure 4-2: Langendorff retrograde perfusion system, modified to induce de novo acute 
heart failure (above); perfusion of the isolated rat heart via the cannulated aorta is shown 
(bottom) 
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Protocols for isolated heart perfusions for functional recovery in this section 
Table 4-2: Protocol for different conditions to induce de novo acute heart failure 








100 em H2O; 20 em H2O; 100 em H2O; 
no FFA 1.3mM FFA 1.3mM FFA 
Stabilization .. • . 
Glucose (mM) 11.1 5 5 or 
Or 2.5 2.5 
Adrenaline (M) None 10-6 None 
Or 10-8 
Or 10-10 
Pacing (BPM) None 150 None 
Or 300 
Calcium (mM) 1.3 1.3 1.3 
Or 2.5 
The experiments in each group were performed as follows: 
• 	 For experiments examining hyperadrenergic stimulus to induce acute 
heart failure: 
The protocol consisted of 3 phases: stabilization, AHF phase and recovery. 
Glucose concentration for all hearts was maintained at 11_1 mmol/L in 
stabilization phase _In the AHF phase, the glucose concentration was dropped 
to 2_5mmol/L and fatty acids (1_3mmoI/L) were introduced in the perfusate. 
Adrenaline 10-6 or 10-8 or 10-10 M was added to the hearts in this phase. The 
AHF phase was followed by recovery phase where the glucose and fatty acid 
concentration was same as the AHF phase and adrenaline infusion was 
stopped. 
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• 	 For experiments examining the effect of glucose modulation to induce 
acute heart failure: 
The protocol as described previously consisted of 3 phases: stabilization, AHF 
and recovery. Stabilization phase was characterized by perfUSion by 
11.1 mmol/L glucose, in the AHF phase, fatty acids (1.3mmoI/L) were added 
and the glucose concentration was either 2.5mmol/L or 5mmoi/L in the 
perfusate. This phase was followed by recovery phase where the fatty acid 
and glucose concentration was maintained as the AHF phase. 
• 	 For experiments examining the effect of calcium modulation to induce 
acute heart failure: 
The basic protocol in stabilization phase was similar to the experiments 
described above. The calcium concentrations in AHF and recovery phase 
were altered to 1.3mmollL or 2.5mmollL. No adrenaline was added to the 
hearts and glucose concentration was at 2.5mmollL in AHF and recovery 
phase. 
• 	 For experiments involving pacing to induce acute heart failure: 
The protocol for stabilization phase was same as in the other groups. In the 
AHF phase, fatty acids (1.3mmoIlL) were introduced to the perfusate and 
glucose concentration was reduced to 2.5mmollL. The hearts were paced at 
either 150 or 300 beats per minute (BPM) in the AHF phase. The pacing was 
stopped in the recovery phase and the substrate concentrations in the 
perfusate were same as those in the AHF phase. 
End points 
The functional parameters measured were heart rate (HR), left ventricular developed 
pressure (L VDP) , rate-pressure product (RPP), while functional recovery of the heart 
was calculated as the percentage of RPP against baseline stabilization values. We 
also monitored left ventricular end systolic pressure (LVESP) and left ventricular end 
diastolic pressure (LVEDP). 
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Statistical analysis 
All statistical analysis was done using InStat software. The data are expressed as 
mean ±the standard error of mean (SEM). Tukeys test was performed between 
multiple groups with p<0.05 was considered significant. The sample size in these 
experiments was n=6-B. 
RESULTS 
Addition of adrenaline to induce acute heart failure 
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Con Adr Adr Adr Con Adr Adr Adr 
Stab 10-6 10-8 10-10 Ree 10-6 10-8 10-10 
Stab Stab Stab Ree Ree Ree 
Figure 4-3: Effect of adrenaline on heart rate (HR)- Stabilization phase; Con- Control; Adr­
Adrenaline; Rec- Recovery phase (*- p<O.05 vs. Adr 1O-6Rec; Tukey-Kramer Multiple 
Comparisons Test) 
The stabilization phase heart rate for all hearts was 355.B±16.4 BPM for controls, 
300.B±6.0 BPM for hearts treated with 10-6 M adrenaline, 290.0±16.9 for hearts 
treated with 10-8 M adrenaline and 314.2±1B.9 BPM for hearts treated with 10-10 M 
adrenaline. (Fig 4-3) The recovery hearts rates for the groups were: 50.2±1B.1, 
31 .0±14.7, 71.0±2B.6 and 146.6±4B.9 BPM respectively . The stabilization values for 
all groups were significant over their respective recovery groups. Hearts treated with 
adrenaline 10-10 M had a better recovery than hearts treated with 10-6 M with p<0.05. 
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Con Adr Adr Adr Con Adr Adr Adr 
Stab 10-6 10-8 10-10 Ree 10-6 10-8 10-10 
Stab Stab Stab Ree Ree Ree 
Figure 4-4_- Effect of adrenaline on left ventricular developed pressure (L VDP)- Stabilization 
phase; Con- Control; Adr- Adrenaline; Rec- Recovery phase. (ns- not significant vs. 
adrenaline treated groups in rec; Tukey-Kramer Multiple Comparisons Test) 
Stabilization LVDP for control, hearts treated with 1Q-6moIlL adrenaline, 10-8mo1/L 
adrenaline and 10-1omo1/L adrenaline were: 86.8±1 .5, 85.3±1.5, 86.2±1.9 and 
88.5±2.5 mmHg respectively. (Fig 4-4) The recovery LVDP for these groups was 
68.0±24.1, 34 .6±15.8, 26.1 ±8.6 and 21 .7±8.3 mmHg respectively. There was no 
statistical significance between groups in the recovery phase. 
Effect of adrenaline on recovery rate-pressure product 
The stabilization values were significantly higher than their respective recovery 
values but there was no significant difference between the various groups in the 
recovery phase. (Fig 4-5)Controls had a mean RPP of 29196±1654, hearts treated 
with 10-6 ,10-8,10-10 M adrenaline had RPP values of 25677±607, 24896±1105 and 
27956±2239 in the stabilization phase respectively. At the end of recovery phase, 
the RPP of these four groups was: 4087±1475, 2082±954, 2760±1108 and 
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Con Adr Adr Adr Con Adr Adr Adr 
Stab 10-6 10-8 10-10 Ree 10-0 10-8 10-10 
Stab Stab Stab Ree Ree Ree 
Figure 4-5: Effect of adrenaline on rate pressure product (RPP) . Stab- Stabilization phase; 
Con- Control; Adr- Adrenaline; Rec- Recovery phase; ns- not significant vs. adrenaline 
treated groups in rec; Tukey-Kramer Multiple Comparisons Test 
Table 4-3: Effect of adrenaline administration on systolic and diastolic pressure and 
coronary flow 








Stabilization 87.2±2.6 87.2±2.1 95.6±2.1 94.9±2.1 
Recovery 113.7±19.3 68.7±15.2 71.1±16.2 22.5±7.8*** 








Stabilization O.9±1.4 1.8±2.3 9.4±1.4 6.3±1 .1 
Recovery 45.6±11.4­ 34.0±12.01l' 45.0±8.7**t O.8±3.6 








Stabilization 8.5±O.3 9.4±O.3 9.3±O.2 8.9±O.4 
Recovery 10.5±O.3 10.8±O.4 10.5±O.3 10.1±O.4 
Table 4-3: *u_ p<O.001 VS. Adrenaline 10-10M Stabilization; ###- p<O.001 vs. Stabilization; 
#- p<O.05 vs. Stabilization 
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In recovery phase the diastolic pressure with adrenaline 10-10M was significantly 
lower (p<0.01 ) than adrenaline concentration 10-8 M. Recovery phases of adrenaline 
controls, 10-6 M (p<0.001) and 10-8 M (p<O.OS) were significantly higher than their 
values in the stabilization phase . There was no significant difference between 
coronary flows amongst the groups. (Table 4-3) 
Summary 
Provision of adrenaline reduced the recovery of the hearts when administered in the 
AHF phase. However, adrenaline at 1 0-1oM concentration had a very high recovery in 
contractility while adrenaline at a concentration of 10-6M had a very poor contractility. 
Despite the statistical insignificant changes in rate pressure product, adrenaline at 
10-8M concentration seemed to reduce both heart rate and LV developed pressure. 
Hence, adrenaline at 10-8M concentration will be considered for further experiments. 
RESULTS 
Alteration of glucose in perfusate 
Effect of alteration of glucose concentration on heart rate 
The stabilization heart rates for hearts perfused with Sand 2.Smmol/L glucose 
respectively were (Fig 4-6): 270.4±7.8 and 279.6±16.3 BPM. The hearts perfused 
with Smmol/L glucose in the AHF and recovery phase had a significantly improved 
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Glucose Glucose Glucose Glucose 
Stab Stab Recovery Recovery 
Figure 4-6: Effect of glucose alteration on heart rate (HR) ; ***- p<O.001 vs. 2.5mM glucose 
recovery; Tukey-Kramer Multiple Comparisons Test 
Effect of glucose alteration on left ventricular developed pressure 
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Figure 4-7: Effect of glucose alteration on LVDP; ns- not significant vs. 2.5mM glucose 
recovery; Tukey-Kramer Multiple Comparisons Test 
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The stabilization values of LV developed pressure for hearts perfused with 5mmoi/L 
and 2.5mmol/L glucose were 84.3±0.6 and 83.8±2.2 mmHg respectively. (Fig 4-7) 
After an episode of AHF and subsequent recovery, the hearts perfused with 5mmollL 
glucose had an LV developed pressure of 42.1 ±3.4mmHg and those perfused with 
2.5mmol/L glucose had LVDP of 49.4±20.5mmHg. This change was not significant 
between groups in the recovery phase. 
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Figure 4-8: Effect of glucose alteration on RPP; ** p<O.01 vs. 2.5mM glucose recovery; 
Tukey-Kramer Multiple Comparisons Test 
Rate-pressure products for the stabilization period of the hearts perfused with 
5mmollL glucose and 2.5mmollL glucose were 22781 ±515 and 23368±1004. (Fig 4­
8) At the end of the recovery phase, hearts perfused with 5mmoi/L glucose had 
significantly improved rate pressure product values as compared to the hearts 
perfused with 2.5mmol/L glucose (8236±1290 vs . 2254±1300). This increase was 
due to the improved heart rate between groups. 
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Table 4-4: Effect of glucose alteration on systolic, diastolic pressure and coronary 
flow: 
Systolic Pressure (mmHg) 
2.SmmollL Glucose SmmollL Glucose 
Stabilization 89.5±1.5 87.5±2.0­
Recovery 68.8±12.3 41.5±3A* 
Diastolic Pressure (mmHg) 
2.SmmollL Glucose SmmollL Glucose 
Stabilization 5.6±2.1 3.1 ±1.5 
Recovery 19.6±16.6 O.O±O.6 
Coronary flow (ml) 
2.SmmollL Glucose SmmoliL Glucose 
Stabilization 8.8±OA 9.0±O.3 
Recovery 10.3±O.5 11.3±O.2 
Table 4-4: ###- p<O.001 vs. Stabilization; *- p<O.05 vs. Recovery 2.5mmmollL glucose 
Summary 
The reduction of glucose in the perfusate from hyperglycaemic11.1 mmol/L to 
physiologic 5mmoi/L level had better recovery as compared to hearts perfused with 
2.5mmol/L glucose. The reduced glucose availability in the 2.5mmol/L glucose 
perfused hearts in combination with the elevated fatty acids in the perfusate 
worsened the heart failure, thereby providing a low recovery value to act as a 
baseline concentration in the remaining experiments described in this thesis. (Table 
4-4) 
RESULTS 
Calcium modulation as a model of acute heart failure 
Calcium plays an important role in the contraction-relaxation of the cardiomyocytes. 
A overload of calcium may lead to arrhythmias, often seen in CHF.112 Our hypothesis 
tests the acute calcium alteration in the perfusate to induce AHF. After 30' 
stabilization period, we studied the effects of normal (1.3mmoI/L) calcium and high 
(2.5mmoI/L) calcium perfusate concentrations on the heart rate. 
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Figure 4-9: Effect of high calcium on heart rate; ns- Not significant vs. High Ca recovery; 
TUkey-Kramer Multiple Comparisons Test 
After 30' stabilization period, heart rate normal (1.3mmoI/L) calcium and high 
(2 .5mmoI/L) calcium were 309.6±10.7 vs . 321.6±1B.0 BPM respectively . (Fig 4-9) 
After 35' of AHF phase and 30' of recovery phase, heart rates of normal calcium 
group were 71 .B±45.0 BPM while the recovery heart rates in the high calcium group 
were 3.3±3.3 BPM. (p>0.05; not significant vs. high calcium) 
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Figure 4-10: Effect of high calcium on LVOP; * p<O.05- vs. High Ca recovery; TUkey-Kramer 
Multiple Comparisons Test 
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At the end of stabilization, the LVDP in the normal calcium concentration group was 
87.0±1.3 mmHg while that in the high calcium group was 81.5±6.4 mmHg. (Fig 4-10) 
In the recovery phase, hearts with normal calcium (1.36mmoI/L) exhibited LVDP of 
80.4±31.7 while those with high calcium (2.5mmoI/L) had a LVDP of 0.9±0.4 mmHg 
respectively (p<0.05)for recovery with normal calcium vs. recovery with high calcium) 

















Co ntrol High Ca Control High Ca 
Stabzn Stabzn Recovery Recovery 
Figure 4-11: Effect of high calcium on RPP; ns- Not significant vs. High Ca recovery; Tukey­
Kramer Multiple Comparisons Test 
Rate pressure product in the hearts perfused with 2.SmmoliL was very poor (2±2) 
owing to the poor recovery heart rate and LV developed pressure when compared 
against 1.3mmoliL Ca2 + in perfusate (5915±2690). These values were however, 
statistically insignificant. (Fig 4-11) 
Table 4-5: Effect of calcium modulation on systolic, diastolic pressure and coronary 
flow 
Systolic Pressure (mmHg) 
Control High calcium 
Stabilization 86.7±2.0 84.2±6.3 
Recovery 129.6±10.0** 54.6±21.5 







 Coronary flow eml) 
Control I High calcium 
9.5±0.6 I 
[ Recovery -- ­ L 11.5±0.6 I 
Table 4-5: **- p<O.01 vs. Recovery control 
The increase in systolic pressure in controls was statistically significant vs. hearts 
perfused with high calcium (p<0.01). There was no significant change in the coronary 
flow between controls and high calcium treated hearts. (Table 4-5) 
Summary 
The high concentration of calcium in the perfusate was detrimental for the hearts 
which showed almost no recovery. Hence, this model to induce acute heart failure 
was too severe and was discarded. We decided to maintain calcium concentration in 
our perfusate at 1.3mmollL in all phases in all experiments described in the following 
sections. 
RESULTS 
Pacing as a model to induce acute heart failure 
We next examined the effects of pacing on heart rate. 
Effect ofpacing on recovery heart rate 
The stabilization HR for controls, hearts paced at 150 BPM and 300 BPM were 
351.1±18.1, 290.8±9.1 and 288.6±15.9 respectively. In the recovery phase, the heart 
rates for the samE~ groups were: 54.4±28.3, 92.0±64.4 and O.O±O.O BPM 
respectively. The hearts paced at 300 BPM showed no recovery. 
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Effect of pacing on recovery left ventricular developed pressure 
Stabilization values for L VDP in controls, in hearts paced at 150 and in hearts paced 
at 300 BPM were 86.7:t2.3, 84.7±1.6 and 85.6±2.3 mmHg respectively. The recovery 
LVDP for the same groups was 37.7±21.7, 19.1±14.8 and 1.1±0.5 mmHg 
respectively. There was no significant difference between the groups in the recovery 
phase. 
Effect of pacing on mcovery rate pressure product 
The rate-pressure product values were: 30506±1978 for controls, 24612±621 for 
hearts paced at 150 BPM and 24717±1576 for hearts paced at 300 BPM in the 
stabilization phase of the protocol. 
The recovery values for control and hearts paced at 150 BPM were: 3478±2248, 
2136±1547; hearts paced at 300 BPM had no recovery. 
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Table 4-6: Effect of paGing on systolic and diastolic pressures and coronary flow 
~" 
Systolic Pressure (mmHg) 
Control Pacing 150 BPM 
""-""-"" 
Pacing 300 BPM 
I Stabilization 88.0±4.1 87.0±3.8 90.5±5.2 




Diastolic Pressure (mmHg) 

Control Pacing 150 BPM Pacing 300 BPM 

r-Stabilization 1.3±1.8 2.3±2.7 4.8±4.0 
Recovery L,9.6±9.2, 35.1±11.5 , 62.6±16.4 
~ \---.. "- -- - ­
i Coronary flow (ml) 
! ""'­!Pacing 150 BPM Pacing 300 BPM Controli 
I 
!9.1±0.6 8.6±0.4 9.0±0.4Stabilization 
! 
i 
I i9.7±0.1 10.3±0.3Recovery '10.3±0.2 
Summary 
Pacing hearts in the ,A,HF phase was a good model to induce de novo AHF, however 
pacing at 300 BPM was too harsh and the hearts showed no recovery. Pacing at 150 
BPM seemed to induce failure and deserves merit but electrical stimulation of the 
heart was not nearly as good as the adrenergic stimulation leading to metabolic side 
effects. Hence, we used different concentrations of adrenaline to induce AHF. 
DISCUSSION 
To our knowledge, our experiments demonstrate the first attempt to establish a 
model of de novo aGute heart failure using isolated rat hearts. We tested three 
conditions to induce l\HF: addition of adrenaline, pacing and increasing the calcium 
concentration in the acute heart failure phase and in the case of high calcium­
induced AHF, we continued high calcium in the recovery phase. 
Addition of adrenaline in our model mimics the hyperadrenergic stimulus associated 
with Takotsubo cardiomyopathl6 and also an acute-on-chronic heart failure situation 
where the circulating catecholamines are elevatedY Our experiments with different 
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concentrations of adrenaline revealed that the concentration of adrenaline at 10-10M 
was too weak to induce heart failure due to the recovery of heart rate subjected to 
this concentration of adrenaline being the highest observed compared to the other 
groups. On the other hand, a concentration of 10-6M had the worst recovery of heart 
rate when compared to all the other groups. Adrenaline at 10-8M had a recovery 
similar to the control hearts and was considered a threshold recovery. Previous 
experiments in our lab in 1983 tested different concentrations of adrenaline on the 
release of lactate dehydrogenase (LDH) and found that at a concentration of 10-8M, 
there was oxygen wastage and decreased pressure work in the hearts. 70 The 
absence of adrenaline in control hearts was similar to those treated with 10-8M in our 
experiments, but in order to simulate the adrenergic stress situation, with expected 
metabolic changes, and not only focusing on the haemodynamic parameters; we 
chose to include adrenaline in our model of acute heart failure. 
Pacing-induced heart failure has been used extensively to induce chronic heart 
failure in dogs by various authors.111, 114-117 These authors examined the effect of 
long-term pacing as a model of chronic heart failure in canines mostly focusing on 
end stage heart failure and examining mitochondrial function and metabolic changes 
in these hearts. To our knowledge, there is a lack of a model of AHF which uses 
pacing to induce acute failure in rodents. We compared non-paced hearts to hearts 
paced at 150 and 300 BPM respectively in the AHF phase of our protocol. Hearts 
paced at 300 BPM in the AHF phase had no recovery, proving that this pacing rate 
was too severe and was hence discontinued. Pacing at 150 BPM is a good model to 
induce AHF and is worthy of future work, being completely reversible thus permitting 
the researcher to monitor metabolic changes after recovery.118 However, clinical or 
large animal studies using pacing as an acute stress to induce AHF are missing. We 
are interested in a metabolic model of acute heart failure with an adrenergic stimulus 
causing metabolic changes, and hence we decided to use adrenaline instead of 
pacing. 
High calcium in the pl~rfusate as a model to induce acute heart failure was tested in 
the AHF phase of our protocol. Heart failure is associated with mitochondrial 
changes.5o Calcium plays an imperative role in the contraction of the heart. 
Abnormalities in the calcium concentration in the mitochondria may trigger lethal cell 
pathways like apoptosis. 119 We examined the effect of increased calcium in the 
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perfusate to induce AHF and observed the recovery in our model. When the 
concentration of calcium in the perfusate was raised from 1.3mmol/L to 2.5mmoI/L, 
there was absolutely no recovery in both heart rate and contractility hence, it was 
concluded that the model was clearly too severe. The lack of recovery prompted us 
to discontinue this model for our further experiments; however, modulation of 
calcium in an acutely failing heart is an important model to study cell death 
associated with heart failure and needs further work to fully understand its merits. 
We conclude from these experiments that addition of adrenaline, pacing, change of 
calcium concentration and reduction of glucose in perfusate all induce AHF most 
likely due to stimulation of different pathways. However, for this thesis, we have 
focused on adrenaline (10-8moI/L) and reduction of glucose from physiological 
5mmoi/L to 2.5mmol/L in perfusate to induce AHF. 
i ISOLATED RAT HEART 
•

[ LOW PERFUSI~N PRESSURE 1 
~ 

GLUCOSEADRENERGIC PACING CALCIUM 
STIMULATION MODULATION ALTERATION 
IDE NOVO ACUTE· HEART FAILURE i 
Figure 4-12: Validation of models to induce AHF 
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Models of acute heart failure 
Based on our different models of de novo AHF, we focus on two models of AHF, one 
without and one with adrenaline: 
The model without adrenaline consisted of three phases: Stabilization phase, AHF 
phase and Recovery phase 
• 	 The stabilization phase is characterised by the perfusion pressure being kept 
at 100 cm H~,O with glucose (11.1 mmol/L) as the sole substrate in the 
perfusate 
• 	 The AHF phase is characterised by lowering the perfusion pressure from 
100 cm H20 to 20 cm H20. The glucose concentration in the perfusate is 
dropped to 2.~)mmoI/L and fatty acids (1.3mmoI/L) are introduced into the 
perfusate 
• 	 In the recovery phase, the perfusion pressure is returned to 100 cm H20 
while keeping the substrate concentration in the perfusate at the same level 
as in the AHF phase. 
STABI LlZATI ON AHF RECOVERY 

30' 35' 30' 

0' 
 I 	 I 
 95' 
11.lmM Glu(:ose; 2.5mM Glucose; 2.5mM Glucose; 
noFFA 1.3mM FFA 1.3mM FFA 
100cm H2O 20 cm H2O 100 em H2O 
Figure 4-13: Protocol for model of AHF without adrenaline (model 1) 
The severe model of AHF consists of three phases: stabilization phase, AHF 
phase and recovery phase. 
• 	 The stabilization phase is characterised by a perfusion pressure of 100 
cm H20 with glucose (11.1 mmol/L) as the sole substrate in the 
perfusate 
• 	 In the AHF phase, the perfusion pressure is dropped from 100 cm H20 
to 20 cm H20 and the glucose concentration is reduced to 2.5mmol/L 
while fatty acids are introduced at 1.3mmol/L in the perfusate. 
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Adrenaline 10-8M is added in this phase to promote the uptake of fatty 
acids 
• 	 Recovery phase involves the perfusion pressure returning back to 
100cm H20 while the substrates in the perfusate are maintained at the 
same level as in AHF phase. 
STABILlZAl"ION AHF RECOVERY 

30' 35' 30' 

0' I 	 I 95' 
1l.lmM Glucose; 2.5mM Glucose; 2.5mM Glucose; 
no FFA 1.3mM FFA; Adr 10-8 M; 1.3mM FFA 
100 cm H2O 




TESTING METABOLIC AGENTS 
FOR RECOVERY FOLLOWING 
DE NOVO ACUTE HEART 
FAILURE 
INTRODUCTION 
A failing heart is metabolically associated with reduced production of ATP to sustain 
its function. 12o Carbohydrates and fatty acids are the essential fuels for the heart in 
the fed and fasted state respectively. After a carbohydrate rich meal, the amounts of 
glucose are elevated and insulin secretion is high, which reduces the releases of free 
fatty acids from the adipose tissue, thus promoting carbohydrates as major source 
(almost 75%) of energy. In the fasted state however, blood free fatty acid levels are 
raised and are oxidized preferentially over glucose. Fatty acids take up to 70% 
oxygen to generate energy (See table 5-1). 29In an ischaemic heart, the enzyme 
pyruvate dehydrogenase is inhibited, thus reducing the amount of glucose uptake 
and fatty acids become the main source of energy. Malonyl CoA is inhibited by 
adenosine mono phosphate- activated protein kinase (AMPK) and protective 
glycolysis is inhibited by inhibiting malonyl CoA. This leads to fatty acid oxidation 
which is "expensive" and deleterious to the heart.121 Glucose via glycolysis generates 
ATP and is economica' as compared to fatty acids. 
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Table 5-1: Fuels of the heart: ratio of oxygen uptake29 
Glucose Pyruvate Lac1ale Total CHO FFA +- (TG) 
Conditions (OER %) (OER 04.) (OER %) (OEA %) (OEA %) 
Insulin. low glucose4 6 44 51 101 3 
Feeding 92 5 
CHQ mealo 68 4 28 100 
Upidmeal 







30 + (SO) 
34 
Exercise 16 0 61 n 21 
Exercise. recovery 21 2 J6 59 36 
Fasting ovornlght 27 1 11 38 62 + (14) 
In 1962, Sodi-Pallares122 infused glucose-insulin-potassium in patients with 
myocardial infarction with the hypothesis that it would lessen arrhythmias by 
improving the polarization in injured cells by potassium. There have been conflicting 
data in the literature about this concept. With the aim of increasing uptake of glucose 
and reducing that of FFA, provision of glucose-insulin-potassium (GIK) treatment has 
been shown to be cardioprotective against acute myocardial infarction in both 
experimental and clinical studies. 123,124 However, GIK has not been tested in acute 
heart failure. We tested the provision of glucose as a therapy in our model of de 
novo acute heart failure. We also tested the administration of insulin in the recovery 
phase to increase the uptake of glucose. We also test our hypothesis that metabolic 
therapy by glucose and insulin improves functional recovery after an episode of AHF 
and reduces cell death caused byapoptosis. 
These experiments were done in two models of de novo AHF. The AHF phase in the 
mild model was characterized by reduced perfusion pressure, reduction of glucose 
concentration and introduction of supra-physiological levels of free fatty acids. The 
severe model had hyperadrenergic stimulus in form of adrenaline in the acute heart 
failure phase along with reduced perfusion pressure and change in substrate 
concentration. 
These experiments had three phases: stabilization, production of AHF and recovery. 





concentration in the AHF phase was 2.5mmol/L and the FFA concentration was 
1.3mmol/L with the perfusion pressure at 20cm H20. In the recovery phase, half the 
hearts were perfused with 11.1 mmol/L glucose while the other half was perfused 
with 2.5mmol/L. The FFA concentration was 1.3mmol/L in all hearts. This phase had 
a perfusion pressure or 100cms H20. 
HYPOTHESIS 
We hypothesized that metabolic treatment by glucose and insulin would improve the 
functional recovery of the hearts after an episode of de novo acute heart failure. 
ACUTE HEART FAILURE 
? . 
Metabolic therapy by 
glucose and insulin to 
counter effects of fatty 
acids and adrenaline 
IMPROVED FUNCTIONAL 
RECOVERY 
Figure 5-1: Diagram hypothesizing improved recovery after treatment with glucose and 
insulin 
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MATERIALS AND METHODS 
Animals 

As previously described in chapter 4. 

Isolated rat heart perfusions 





Protocols for isolated heart perfusions for functional recovery: and Western 
blotting in this section 
STABILIZATION AHF RECOVERY 
30' 35' 30' 
0' I I 95' 
100 em H20 100 em H20 
. . ... Recovery 
Modell ll.lmmol/L 2.Smmol/L Glucose; 2.Smmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA 1.3mmol/L FFA 
Modell ll.lmmol/L 2.Smmol/L Glucose; ll.lmmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA 1.3mmol/L FFA 
Model 2 ll.lmmol/L 2.Smmol/L Glucose; 2.Smmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; 1.3mmol/L FFA 
IO·8M Adrenaline 
Model 2 ll.lmmol/L 2.Smmol/L Glucose; ll.lmmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; 1.3mmol/L FFA 
IO·8M Adrenaline 
Model 2 ll.lmmol/L 2.Smmol/L Glucose; ll.lmmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; 1.3mmol/L FFA; O.3mU 
IO·8M Adrenaline Insulin 
Model 2 ll.lmmol/L 2.Smmol/L Glucose; ll.lmmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; 1.3mmol/L FFA 
IO·8M Adrenaline 
Model 2 ll.lmmol/L ll.lmmol/L Glucose; ll.lmmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; 1.3mmol/L FFA 
IO·8M Adrenaline 
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Protocol for isolated rat heart perfusion to evaluate the effect of metabolic 
therapy on cell death 
STABILIZATION AHF RECOVERY 
30' 35' 20' 
0' 85'I I 
Glucose; no FFA Glucose; no FFA 
ll.lmmol/L Glucose; 
no FFA 
Model 2 ll.lmmol/L 2.Smmol/L Glucose; 2.Smmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; 1.3mmol/L FFA 
lO-8M Adrenaline 
Model 2 l l.lmmol/L 2.Smmol/L Glucose; 2.5mmol/L Glucose; 
Glucose; no FFA l.3mmol/L FFA; 1.3mmol/L FFA; 
lO·8M Adrenaline O.3mU Insulin 
Model 2 l l.lmmol/L 2.Smmol/L Glucose; ll.lmmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; 1.3mmol/L FFA 
lO-8M Adrenaline 
Model 2 ll.lmmol/L 2.5mmol/L Glucose; ll.lmmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; l.3mmol/L FFA; 
lO-8M Adrenaline O.3mU Insulin 
Western blots to examine the effect of metabolic therapy on cell death 

Lowry's method of protein quantification was used to assess the quantity of 

cytochromeC in the samples and the Western blots were run as described in the 















Effect of high glucose on heart rate when administered in recovery phase of 
model 1 
The mean heart rates in stabilization for controls and hearts treated with high 
glucose were: 286.8±12.6 BPM and 281 .0±7.3 BPM respectively. (Fig 5-2) Recovery 
for controls was reduced to 106.5±37.3 BPM. Hearts treated with high glucose had a 
recovery HR of 204.0±21 .2 BPM. Treatment with high glucose in recovery phase of 






















Figure 5-2: Effect of glucose on heart rate in recovery phase of model 1; *- p<O.05 vs. 
control recovery; Tukey-Kramer Multiple Comparisons Test 
Effect of high glucose on left ventricular developed pressure (L VDP) 
Stabilization values for controls and hearts treated with high glucose were 96.0±5.0 
and 90.0±2.1 mmHg. Controls had a recovery LVDP of 58.4±13.3mmHg and 
treatment with high glucose had LVDP of 59.8±2.5 mmHg. Treatment with high 
































Control High Control High 
Stabzn Glucose Recovery Glucose 
Stabzn Recovery 
Figure 5-3: Effect of glucose on LVDP in model 1; ns- not significant; Tukey-Kramer Multiple 
Comparisons Test 
Effect of glucose on rate pressure product 
The mean stabilization RPP for control hearts was 22259±4466 and that for hearts 
treated with high glucose was 25018± 717; After 35' of AHF and 30' of recovery 
phase, hearts treated with low glucose showed a recovery RPP of 5018±1439 while 
those treated with high glucose had a RPP of 12024±1134. (Fig 5-4) Treatment with 
glucose in the recovery phase of the mild model significantly increased the RPP 













Co ntrol High HighControl 
Stabzn Glucose GlucoseRecovery 
Stabzn Recovery 
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Figure 5-4: Effect of glucose on RPP in model 1; ###- p<O.001 vs. control recovery;##­
p<O.01vs. high glucose recovery; **- p<O.01 vs. control recovery; Tukey-Kramer Multiple 
Comparisons Test 
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Table 5-2: Effect of glucose on systolic pressure, diastolic pressure and coronary 
flow in model 1 
Systolic pressure (mmHg) 
Control High glucose 
Stabilization 97.1 ±4.7 93.8±1.2 
Recovery 100.7±11 .7 74.8±6.3 
Diastolic Pressure (mmHg) 
Control High glucose 
Stabilization O.O±1.4 6.1±1.3 
Recovery 42.2±7.2 14.9±6.5** 
Coronary flow (ml) 
Control High glucose 
Stabilization 9.0±O.3 9.6±O.5 
Recovery 10.1±O.4 10.8±O.5 
Table 5-2: **- p<O.01 vs. Recovery control 
The diastolic pressures in stabilization phase for both groups were 2.4±1.3mmHg. 
However, following AHF and recovery phase, hearts treated with low glucose had a 
recovery diastolic pressure of 42.2±7.2mmHg. (Table 5-2) Treatment with high 
glucose in the recovery phase significantly decreased this to 14.9±6.5mmHg with the 
p<O.01 vs. recovery with low glucose. 
Summary 
In our model 1 of de novo AHF where AHF was induced by reducing the perfusion 
pressure and altering substrate concentration in the perfusate, treatment with high 
(11.1 mmol/L) glucose improved the functional recovery by increasing the heart rate 
and also improved the relaxation of the ventricles by reducing the L VEDP. 
The following experiments shall be performed using model 2 which not only has 
reduction of perfusion pressure and substrate alteration in the perfusate, but a 




Effect of glucose on recovery in model 2 of AHF 
Glucose was cardioprotective when tested in our model 1. Hence, we decided to test 
glucose in model 2 of AHF. We tested glucose (11 .1mmoI/L) again in the recovery 
phase of the protocol; however, we added adrenaline (10-8M) to the existing 
hypotension and low (2.5mM) glucose and FFA (1 .3mM) in the AHF phase. 














Stabznwith Stabznwith Rec with Low Rec with high 
Low glucose high glucose glucose glucose 
Figure 5-5: Effect of glucose on HR in model 2; ns- not significant vs. Rec with low glucose; 
Tukey-Kramer Multiple Comparisons Test 
Stabilization heart rates for low glucose group were 306.5±15.0 BPM and those for 
high glucose hearts were 277 .6±14 .B BPM. (Fig 5-5) Recovery with low glucose in 
the severe model had a HR of 2B.5±15.0 BPM while the recovery with high glucose 
was 36.7±25.0 BPM. The recovery between low glucose and high glucose in the 
recovery phase is statistically insignificant. 
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Stabznw ith Stabznwith Rec with Low Rec with high 
Low glucose high glucose glucose glucose 
Figure 5-6: Effect of glucose on L VDP in model 2; ns- not significant vs. Rec with low 
glucose; Tukey-Kramer Multiple Comparisons Test 
The stabilization value of LVDP for hearts with low and high glucose was: 87.8±2.6 
and 89.0±2.8 mmHg respectively. (Fig 5-6) After treatment with low glucose in 
recovery phase, the LVDP was 24 .9±12.7mmHg while the LVDP after treatment with 
high glucose was 39.0±16.9mrnHg. These results between the groups in the 
recovery phase were statistically insignificant. 
Effect of high glucose on rate pressure product 
The mean RPP in stabilization for low glucose hearts was 26924±1493 and that for 
hearts treated with high glucose was 24681±1330. (Fig 5-7) The RPP after treatment 
with low glucose was 1559±1234 while that after treatment with high glucose was 
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Stabznwith Stabznwith Rec with Low Rec with high 
Low glucose high glucose glucose glucose 
Figure 5-7: Effect of glucose on RPP in model 2; ns- not significant vs. Rec with low 
glucose; Tukey-Kramer Multiple Comparisons Test 
Table 5-3: Effect of glucose on systolic, diastolic pressures and coronary flow in 
model 2 
SystoliC Pressure (mmHg) 
Low glucose High glucose 
Stabilization 89.6±1.8 87 .3±3.0 
Recovery 57.1±18.6 69.2±17.3 
Diastolic Pressure (mmHg) 
Low glucose High glucose 
Stabilization 1.7±2.6 O.O±1 .7 
Recovery 32.3±7.9** 30.2±7.5** 
Coronary flow (ml) 
Low glucose High glucose 
Stabilization 9.4±O.3 9.3±O.4 
Recovery 10.7±O.4 11.1±O.4* 
Table 5-3: **- p<O.01 vs. Respective stabilization values; *- p<O.05 vs. Respective 
stabilization value 
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The effect on diastolic pressure with both high and low glucose treatment in the 
recovery phase increased diastolic pressure as significantly (p<O.01) as compared to 
its respective stabilization phase. The treatment had no significant change on 
systolic pressures. The coronary flow in the high glucose recovery phase was 
significantly (p<O.05) increased over the stabilization phase. (Table 5-3) 
Summary 
The treatment with high glucose in model 2 had no effect on recovery. The proposed 
reason for this is the presence of added adrenaline in AHF phase which may have 
promoted the uptake of FFA as substrates despite the availability of glucose. 
RESULTS 
Effect of glucose and insulin in recovery phase of model 2 
Insulin and glucose have been shown to be cardioprotective in the ischemic­
reperfusion injury due to the activity of insulin that promotes the uptake of glucose in 
the myocardium. 125 Hence we decided to test insulin and glucose in our model with 
adrenaline in AHF phase (model 2). We hypothesize that treatment with insulin and 
high (11.1 mmol/L) glucose improves the functional recovery vs. high glucose in the 
recovery phase. 
Effect of high glucose + insulin treatment on heart rate 
The HR in stabilization phase of hearts treated with high glucose and hearts treated 
with high glucose plus insulin were (Fig 5-8): 277.6±14.8 and 272.0±14.5 BPM 
respectively. In recovery phase, hearts with just high glucose had a recovery HR of 
36.7±25.0 BPM while addition of insulin to the heart improved the HR to 168.5±34.5 
BPM . This improvement in HR was statistically significant with p<O.01 vs. recovery 
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glucose glucose+insulin 
Figure 5-8: Effect of glucose + insulin on HR in model 2; ** p<O.01 VS. Rec with high 
glucose; Tukey-Kramer multiple comparison test 
Effect of high glucose + insulin treatment on left ventricular developed 
pressure 
Hearts treated with high glucose had stabilization phase LVDP of 89.0±2.8 while the 
hearts treated with high glucose+ insulin had stabilization L VDP of 91 .2±4.1 mmHg. 
(Fig 5-9) After subjecting hearts to model 2, the hearts treated with just high glucose 
had a LVDP of 39.0±1 7.0 mmHg while those treated with insulin + high glucose had 
a LVDP of 31.9±7.2 mmHg. These values in the recovery phase between groups 
were statistica lIy insignificant. 
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insulin 
Figure 5-9: Effect of glucose + insulin on LVDP in model 2; ns- not significant VS. Rec with 




Effect of high glucose + insulin treatment on rate pressure product: 
High glucose hearts in the stabilization phase had a RPP of 24681 ±1330 and those 
treated with high glucose+ insulin had stabilization RPP of 24765±1330. (Fig 5-10) 
Treatment with high glucose in recovery phase had a RPP of 2493±1550 while 
insulin combined with high glucose had a recovery RPP of 5176±1 058. Despite the 
slight improvement, these values are statistically insignificant. 
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Stabzn Stabzn Rec with high Rec with high 
high glucose high glucose+ glucose glucose+insulin 
insulin 
Figure 5-10: Effect of glucose + insulin on RPP in model 2; ns- not significant vs. Rec with 
high glucose; Tukey-Kramer multiple comparison test 
Table 5-4: Effect of glucose+ insulin on systolic, diastolic pressures and coronary 
flow in model 2 
Systolic Pressure (mmHg) 
High glucose High glucose + insulin 
Stabilization 87.3±3.0 95 .17±3.2 
Recovery 69.2±17.3 33.4±7.5* 
Diastolic Pressure (mmHg) 
High glucose High glucose + insulin 
Stabilization 0.0±1.7 3.8±1 .1 
Recovery 30.7±7.5 1.5±3.3** 
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Coronary flow (ml) 
High glucose High glucose + insulin 
Stabilization 9 .3±OA 9.S±O.2 
Recovery 11 .1 ±OA 10.0±O 
Table 5-4: *- p<O.05 vs. High glucose recovery; **- P<O.01 vs. High glucose recovery 
Addition of insulin decreased systolic pressure in the recovery phase vs. stabilization 
(p<O.OS). It also reduced the diastolic pressure significantly when compared to HG 
recovery (p<O.01). The coronary flow was had no changes between groups. (Tab 5-4) 
Summary 
The addition of insulin does improve the functional recovery of isolated hearts 
subjected to severe model of de novo AHF. This improvement however, is attributed 
to the increase in heart rate only but not contractility. Addition of insulin also 
significantly improved relaxation of the ventricles by reducing diastolic pressure. 
RESULTS 
Effect of glucose in AHF phase in model 2 
To test if the provision of glucose in the AHF phase is cardioprotective, we compared 
the effects of high (1 1.1 mmollL) or low (2.SmmoI/L) glucose in the AHF phase 
followed by high glucose in recovery phase for both groups. These experiments were 
done in the model 2. 
Effect of glucose in AHF phase in model 2 on heart rate 
In the stabilization phase, hearts perfused with low glucose had a HR of 277.6±14.8 
BPM and the hearts perfused with high glucose in AHF had a stabilization HR of 
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287.1±17.2 BPM. (Fig 5-11) At the end of recovery phase, hearts that had been 
treated with low glucose had a HR of 36.7±25.0 BPM while those that were treated 
with high glucose in the AHF phase had a recovery HR of 229.5±25.6 BPM. This 
increase was very significant with the p value being less than 0.001 vs. hearts 
treated with low glucose. 
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Stabznlow Stabznhigh Rec with low Rec with high 
glucose glucose glucose in AHF glucose in AHF 
inAHF in AHF 
Figure 5-11: Effect of glucose in AHF phase on heart rate in model 2; ***- p<O.001 vs. Rec 
with low glucose in AHF; Tukey-Kramer multiple comparison test 
Effect of glucose in AHF phase in model 2 on left ventricular developed 
pressure 
Stabilization LVDP for hearts treated with low glucose was 89.0±2.8 mmHg and that 
for the high glucose in AHF hearts was 86.7±1 .0mmHg. (Fig 5-12) In recovery 
phase, hearts that were treated with low glucose in AHF had a LVDP of 38.9±16.9 
mmHg while those treated with high glucose in AHF phase had a recovery L VDP of 

































Stabznlow Stabznhigh Rec with low Rec with high 
glucose glucose glucose in AHF glucose in AHF 
inAHF inAHF 
Figure 5-12: Effect of glucose in AHF phase on L VDP in model 2; ns- not significant vs. rec 
with low glucose in AHF; Tukey-Kramer multiple comparison test 
Effect of glucose in AHF phase in model 2 on rate pressure product 
Stabilization values of RPP for hearts treated with low glucose in AHF and hearts 
treated with high glucose in AHF were: 26481±1330 and 24949±1627 respectively. 
(Fig 5-13) The hearts treated with low glucose in AHF phase showed a recovery 
RPP of 2493±1550. The hearts treated with high glucose in AHF phase however, 
had RPP of 11677±2447. This increase was almost 5 times the hearts with low 
glucose in AHF. The data between groups in recovery phase were statistically 






















Stabznlow Stabznhigh Rec with low Rec with high 
glucose glucose glucose in AHF glucose in AHF 
inAHF inAHF 
Figure 5-13: Effect of glucose in AHF phase on RPP in model 2,- *- p<O.05 vs. Rec with low 
glucose in AHF,- Tukey-Kramer multiple comparison test 
Table 5-5: Effect of high glucose in AHF phase on systolic, diastolic pressure and 
coronary flow in model 2 
SystOliC Pressure (mmHg) 
Low glucose in AHF High glucose in AHF 
Stabilization 87.3±3.0 93.2±1.5 
Recovery 69.2±17.3 67.4±14.7 
Diastolic Pressure (mmHg) 
Low glucose in AHF High glucose in AHF 
Stabilization 0.0±1.7 6.4±1.1 
Recovery 30.2±7.5 6.1 ±1.2*** 
Coronary flow (ml) 
Low glucose in AHF High glucose in AHF 
Stabilization 9.3±0.4 10.1 ±0.4 
Recovery 11 .1 ±0.4 12.7±0.3 
Table 5-5: ***- p<O.001 vs. Recovery with low glucose in AHF 
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Treatment with high glucose in the AHF phase in model 2 significantly (p<O.001) 
reduced diastolic pressure when compared against low glucose in AHF, thus 
improving relaxation. There was no significant change in the systolic pressures 
between groups. The coronary flow was increased in the recovery phases versus the 
respective stabilization phases (p<O.05 vs. Low glucose in AHF; p<O.001 vs. High 
glucose in AHF) (Table 5-5) 
Summary 
These experiments show that glucose is protective when administered in the AHF 
phase as it improves the functional recovery by improving heart rate and reducing 
diastolic pressure. There was no effect on the LVDP. 
RESULTS 
Effect of metabolic therapy on cell death 
To test whether metabolic therapy against de novo AHF would reduce the cell death; 
we performed Western blots using model 2 of AHF for cytochrome C (Cyt C) which is 
a marker for apoptosis. Five groups were studied: hearts with no AHF, hearts treated 
with low glucose (LG) in recovery phase, hearts treated with low glucose+ insulin 
(LG+lns) in recovery phase, hearts treated with high glucose (HG) in recovery phase 
and hearts treated with high glucose+ insulin (HG+ Ins) in recovery. Lowry assay 126 
was used to quantify the proteins. After running the gels and transfer, the 
membranes was probed using a CytC antibody and bands were recorded under the 




The hearts were perfused as follows 
Western Blots for Cyt C 
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The insulin, high glucose, high glucose+ insulin were perfused in the recovery phase. 
Lowry protein quantification was performed to analyze the amount of protein, as 
described in the methods chapter. 
RESULTS 
Effects of metabolic therapy on cell death 
No AHF LG AHF LG+ Ins HG AHF HG+ Ins 
B-Actin 
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Metabolic treatment with glucose and insulin combined or individually had no effect 
on the expression of cyt C when hearts were exposed to AHF. 
DISCUSSION 
In our model of de n% acute heart failure, provision of glucose improved functional 
recovery when administered in the recovery phase of model 1 in absence of 
hyperadrenergic stimulus. We propose that this improvement is due to the increase 
of glucose oxidation after acute failure. In a chronically failing heart, glucose 
oxidation is reduced due to elevated fatty acid metabolism27 . From our experiments, 
we propose that infusion of glucose-insulin should be tested as a therapy in acute 
heart failure patients. Glucose reduces the elevated diastolic pressure, thereby 
improving relaxation of the ventricles. Addition of adrenaline in the AHF phase 
reduced the effect of glucose, suggesting that adrenaline promotes fatty acid uptake 
by reducing glucose oxidation, but this proposal merits further work. One way to 
confirm this hypothesis would be to measure the glucose and fatty acid oxidation in 
isolated hearts during the AHF phase. 
Our preliminary experiments shed light on the effect of adrenaline on recovery from 
AHF in our model. Adclition of insulin to glucose when AHF was induced by addition 
of adrenaline improved functional recovery by increasing heart rate and reducing 
diastolic pressure. This effect on increased heart rate suggests stimulation of the 
sinus node due to glucose and insulin. Previously, Senges et a/127 studied the effect 
of glucose-insulin-potassium (GIK) infusion in patients with sinus node dysfunction 
and found that GIK improved sinus node function. This improvement was, however, 
attributed to glucose and insulin and not potassium. Glucose was found to regulate 
the slow inward current which caused the acceleration of the sinus rate in patients 
with sinus node dysfunction, improvement of the SA nodal function and reduction of 
post-stimulatory sinus node recovery time. Our experiments are the first to provide 
insight into the effect of glucose and insulin on the sinus node of an acutely failing 
heart. The future work for experiments in the metabolic group could involve the 
examination of sinus node electrophysiology in an acutely failing heart and treating 
with glucose and insulin and to assess recovery. 
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Insulin as a pharmacological agent activates the survivor activating factor 
enhancement (SAFE) pathwal8 which reduces infarct size after ischaemic­
reperfusion injury. Future work in our experiments could be to examine the 
mechanisms involved in the protective effect of glucose and insulin. Heart failure has 
metabolic implications, hence alterations in the metabolism would be considered as 
a viable treatment. Studies to regulate metabolism in chronic heart failure (CHF) 
patients have shown promising results,116,128,129 but there are no published data on 
metabolism and acute heart failure. Our promising data indicate that reduction in 
fatty acid metabolisrr and elevation of protective glycolysis could be exploited to 
develop therapies against acute heart failure patients. 
Administration of glucose in the AHF phase of our experiments improved the 
functional recovery despite the presence of adrenaline. These data indicate that 
glucose in the acute heart failure phase is cardioprotective. This is relevant to the 
situation of patients coming into the Emergency Room with clinical AHF in a 
hyperadrenergic state and receiving a glucose-insulin drip. Glucose administered in 
the AHF phase should also have an effect on the sinus node and hence improve 
heart rate if there is sinus bradycardia. 
The provision of glucose and insulin and the subsequent improvement in the heart 
rate in failing hearts corresponds to improved sinus node activity. Our data suggests 
this improvement is caused by increasing glycolysis. This could be clarified by the 
measurement of glycolysis in the acutely failing hearts and merits future work. 
Metabolic agents and cell death 
We hypothesized that the functional recovery improvement in hearts treated with 
glucose and insulin would reduce cell death by reducing the expression of Cyt C 
which is released by the mitochondria in response to apoptosis. Our data showed no 
significant reduction ir' levels of Cyt C when treated with glucose, insulin or a 
combination of the two. Cyt C is involved in the early stages of the initiation of 
apoptosis in myocytes. Cyt C, once released by the mitochondria, forms a part of an 
assembly called as apoptosome which has other components including apoptotic 
protease activating factor-1 (APAF-1), procaspase 9 and dATP. 13o The assembly 
activates the caspases which then cause cell death. However, apoptosis is not the 
sole mechansim of death of the cells in the myocardium. Other mechanisms of cell 
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death including necrosis and autophagy need further research in our model of acute 
heart failure. Also, instead of cyt C, observing the activation of other pro-apoptotic 
molecules like caspases will help us understand the mechanism of cell death in 
acute heart failure. 
CONCLUSION 
In absence of an adrenergic stimulus, provision of glucose (11.1 mmol/L) in the 
perfusate improved functional recovery by increasing the heart rate. 
However, this cardioprotective outcome of glucose was abrogated in the presence of 
adrenaline in the AHF phase. Addition of insulin combined with glucose in the 
recovery phase improved the recovery. 
Administration of glucose individually or in combination with insulin had no effect on 
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AHF may be associated with multiple conditions like acute coronary syndromes, 
arrhythmias, hypertension, existing chronic heart failure and kidney dysfunction. In 
acute cases, time is limited; hence the need for pharmacological agents to stabilize 
the cardiovascular system in such patients arises. Many patients with AHF receive 
oxygen, diuretics and vasodilators. 19 These agents help stabilize the patient. 
However, due to the heterogeneity of clinical presentations associated with AHF, 
there is a need for more therapeutic pharmacological agents and for the 
understanding of their underlying mechanisms.Sphingosine-1-phosphate (S1 P) is 
one such molecular agent which reduces infarct size and improves functional 
recovery after ischaemic-reperfusion injury.95 S1 P is cardioprotective by activating 
the Survivor Activating Factor Enhancement (SAFE)84 pathway which involves the 
activation of signal transducer and activator of transcription factor 3 (STAT3). 
Activation of STA T3 improves mitochondrial function by inhibiting the opening of the 
mitochondrial permeability transition pore (mPTP). There is however no study 
examining the effects and molecular mechanisms involved in cardioprotection by 
S1P in an acute heart failure setting. Hence, we decided to test S1P in our model of 
de novo AHF. We also propose that the SAFE pathway is involved in the 
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cardioprotective effect of S1 P in AHF and that it prevents cell death by inhibiting 
cytochrome C release from the mitochondria to improve mitochondrial integrity. 
AG490 is an inhibitor of the JAK/STAT3 pathway and reduces the phosphorylation of 
ST AT3, thus attenuating the SAFE pathway. In ischaemic hearts, AG490 abrogates 
protective SAFE pathway and promotes cell death by increasing the number of 
apoptotic cells.48 
Ranolazine is an anti-anginal drug that reduces cardiac troponin-T and infarct size in 
rats subjected to regional ischaemia. Its metabolic effects include partial suppression 
offatty acid oxidation, hence promoting glycolysis, which should help generate ATP 
in a failing heart.27 Ranolazine ameliorates calcium and sodium homeostasis in the 
heart without any deleterious effects on heart rate or systolic pressure. 131 ,132 It is 
cardioprotective against diastolic heart failure. 132 However, there are no studies that 
report the effect of administration of ranolazine in de novo AHF. We tested whether 
ranolazine administered in our model of de novo AHF improves the functional 
recovery. 
Models used: These experiments were done in two separate models: model 1and 
model 2. AHF in model 1 was induced by changing the substrate concentration 
(2.5mmoI/L glucose and 1.3mmollL fatty acids) and reducing the perfusion pressure. 
Both S1 P and ranolazine were administered in the AHF phase. To test the 
involvement of SAFE pathway activated by S1 P in our model of de novo acute heart 
failure, AG490 was administered in the AHF phase. The recovery phase of these 
hearts also had the same substrate concentration as the AHF phase. The next set of 
experiments were performed using model 2 of AHF where adrenaline was added in 
the AHF phase to make the heart failure more severe in addition to the other 
changes in model 1 (lowering the perfusion pressure and changing the substrate 
concentration in the pertusate). S1 P was added in the AHF as well as in the recovery 
phase. The fatty acid and glucose concentrations were maintained as in model 1 in 
the AHF and recovery phases. 
Ranolazine was tested in model 1 and was administered in AHF phase. The 




We hypothesized that provision of the pharmacological agents sphingosine-1­
phosphate and ranolazine either during an episode of AHF or in the recovery phase 
would improve functional recovery and reduce cell death. 
ACUTE HEART FAILURE 
Pharmacological 
therapy by S1 P and 
? ranolazine to counter. 
adverse effects of 







Figure 6·1: Hypothesis diagram for pharmacological agents 
MATERIALS AND METHODS 
Animals 
As previously described in chapter 4. 
Isolated rat heart perfusions 
Protocols for isolated heart perfusions for functional recovery and Western 
blotting in this section 
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STABILIZATION AHF RECOVERY 

30' 35' 30' 
0' 95'I I 

100cm H20 20 cm H20 100 cm H20 
Recovery 
Modell ll.lmmol/L 2.5mmol/L Glucose; 2.5mmol/L 
Glucose; no FFA 1.3mmol/L FFA; IOnM Glucose; 
SIP 1.3mmol/L FFA 
Model 2 ll.lmmol/l 2.Smmol/L Glucose; 2.5mmol/L 
Glucose; no FFA 1.3mmol/L FFA; IO-8M Glucose; 
Adrenaline; IOnM SIP 1.3mmol/L FFA 
Model 2 ll.lmmol/L 2.5mmol/L Glucose; 2.5mmol/L 
Glucose; no FFA 1.3mmol/L FFA; IO-8M Glucose; 
Adrenaline 1.3mmol/L FFA; 
IOnM SIP 
Stabilization 
The experiments in this section focused on examining the following : 
Is S1P cardioprotective in AHF? 
, The pr~liminary experiments in this group were performed to assess if provision of 
S1 P would improve functional recovery of acutely failing hearts. S1 P was tested in 
both ,Illpdel1 (without adrenaline in AHF) and model: 2 (adrenaline in AHF phase). 
Mechanisms involved in cardioprotection: Is the SAFE Pathway involved? 
The Survivor Activating Factor Enhancement (SAFE) pathway protects the heart 
against ischaemic-reperfusion injury by the activation of janus kinase (JAK) which 
belongs to the family of tyrosine kinases, involved in the transduction of signals from 
the cytosol to the nucleus48 and signal transducer and activator of transcription 3 
. .. 
(STAT3) which confers cardioprotection by reducing infarct size and improving the 
functi6nal.recovery in an ischaemic heart.48 
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Protocol 
STABILIZATION AHF RECOVERY 
30' 35' 30' 
0' I I 95' 
Model 2 ll.lmmol/L 
Glucose; no FFA 
Model 2 ll.l mmol/L 
Glucose; no FFA 
Model 2 ll.lmmol/L 
Glucose; no FFA 
Model 2 11.1mmol/L 
Glucose; no FFA 































Western blots for determination of 5TAT3 in model 2 of AHF 
Protocol for isolated heart perfusion 
Western Blot for STAT3 
STABILIZATION AHF RECOVERY 
30' 35' 7' 







Glucose; no FFA 
ll.lmmol/L 
Glucose; no FFA 
ll.lmmol/L 
Glucose; no FFA 
l l.lmmol/L 































Effect of 51P on cell death in model 2 of AHF 
Protocol for isolated heart perfusion 
Western Blots for Cyt C 
~ 







AHF I Recovery 
Model 2 ll.lmmol/L 2.5mmol/L Glucose; 2.5mmol/L 
Glucose; no FFA 1.3mmol/L FFA; Glucose; 
lO-8M Adrenaline 1.3mmol/L FFA 
Model 2 ll.lmmol/L 2.5mmol/L Glucose; 2.5mmol/L 
Glucose; no FFA 1.3mmol/L FFA; Glucose; 
lO-8M Adrenaline; l .3mmol/L FFA 
lOOnMAG490 
Model 2 ll.lmmol/L 2.5mmol/L Glucose; 2.5mmol/L 
Glucose; no FFA 1.3mmol/L FFA; lO-8M Glucose; 
Adrenaline l.3mmol/L FFA; 
lOnM SlP 
Model 2 l l .lmmol/L 2.5mmol/L Glucose; 2.5mmol/L 
Glucose; no FFA 1.3mmol/L FFA; Glucose; 
lO-8M Adrenaline; 1.3mmol/L FFA; 
lOOnM AG490 lOnM SlP 
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To examine the effect of Ranolazine on functional recovery in model 1 of AHF 
Protocol for ;so/ated hearts 








100 em H2O 20 em H2O 100 em H2O 
AHF Recovery 
Modell l1.lmmol/L 2.Smmol/L Glucose; 2.Smmol/L 
Glucose; no FFA 1.3mmol/L FFA Glucose; 
1.3mmol/L FFA 
Modell l1.lmmol/L 2.Smmol/L Glucose; 2.Smmol/L 
Glucose; no FFA 1.3mmol/L FFA; Glucose; 
SIlM Ranolzaine 1.3mmol/L FFA 
Western blots to examine the effect of metabolic therapy on cell death 
Lowry's method of protein quantification was used to assess the quantity of proteins 
in the samples and the Western blots were run as described in the methods section 
in chapter 2. 
End points 
As previously described in chapter 4. 
Statistical analysis 




Is 51 P cardioprotective? 
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Rec w/o Rec withStab Stab 
SlP SlPCon SlP 
Figure 6-2: Effect of sphingosine-1-phosphate (S1 P) on HR in model 1(Stabzn- Stabilization 
phase; Rec- Recovery phase; S1P- sphingosine 1 phosphate); ## p<O.01 Rec wlo S1P vs. 
Rec with S1P; Tukey- Kramer Multiple Comparison Test 
After 3~ ' of stabilization, heart rates of in both groups had no significant difference. 
(Fig 6-2) However, at the end of recovery phase, hearts which were treated with S1 P 
in the AHF phase had a mean HR of 182.5±25.2 vs. 91.1±25.7 BPM of the control 
hearts (## p<0.01 vs. recovery without S 1 P). 
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Stabzn Stabzn Rec W/O Rec with 
Con SIP SIP SIP 
Figure 6-3: Effect of S 1 P on L VDP in model. (Stabzn- Stabilization phase; Rec- Recovery 
phase; S1P- sphingosine 1 phosphate; L VDP- left ventricular developed pressure); ns- not 
significant vs. rec with S 1 P; T ukey- Kramer Multiple Comparison Test 
The recovery between the two groups was statistically insignificant. The mean 
stabilization LVDP for controls and S1 P hearts were 84.0±1.6 mmHg and 82.8±1.0 
mmHg respectively. (Fig 6-3) On treatment with S1 P in AHF phase the recovery 
LVDP was 32.0±5.3 mmHg vs. 41.1±8.8 mmHg for control hearts. 
Effect of81P in model 1 ofAHF on rate pressure product 
The changes in rate pressure product between the two groups were statistically 
insignificant despite tI-'e treatment with S 1 P. The stabilization values for control and 
S1P group were 22903±990 and 24599±1310 respectively. The recovery values for 
the same groups were 3605±392 vs. 5557±691 respectively. (Fig 6-4) 
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There were no significant differences between systolic pressure, diastolic pressure 
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phase Failure phase ' '-.~." ~..~..~ 
Figure 6-5: Example ofpressure traces in hearts without and with S 1 P 
Summary 
In AHF induced without adrenaline (model 1), S1 P treatment improved heart rate but 
not the LV developed pressure. There was no reduction in diastolic pressure, thus 
suggesting impaired rE~laxation 
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RE5ULT5: 51 P ACTIVITY IN MODEL 2 
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Stabzn Stabzn Stabzn Recovery Recovery Recovery 
Con SlPin SlPin Con SlPin SlPin 
AHF Rec AHF Rec 
Figure 6-6: Effect of S1P on HR in model 2 (Stabzn- Stabilization phase; Rec- Recovery 
phase; S1P- sphingosine 1 phosphate; Con- Control); *- p<O.05 vs. Recovery S1P in AHF; 
ns- not significant; Tukey-Kramer Multiple Comparisons Test 
The stabilization values for control hearts, hearts that were treated with S1 P in AHF 
phase and hearts that had S1 P treatment in recovery phase were: 338.2±31 .0, 
310.4±20.0 and 313.0±20.2 BPM respectively. (Fig 6-6) Recovery when S1 P was 
administered with adrenaline in the AHF phase was 69.6±15.7 while S1 P 
administered in the recovery phase had a HR of 175.17±30.7;the controls had a 
recovery HR of 71 .6±27.4 BPM . Heart rate was increased significantly (p<O .05) 
when S1 P was administered in the recovery phase vs. when S1 P was administered 
in the AHF phase. 
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Stabzn Stabzn Stabzn Recovery Recovery Recovery 
Con SlPin SlPin Con SlPin SlPin 
AHF Rec AHF Rec 
Figure 6-7: Effect of S1 P on LVDP in model 2. (Stabzn- Stabilization phase; Rec- Recovery 
phase; S1P- sphingosine 1 phosphate; Con- Control); ns- no significance between different 
groups in recovery phase; Tukey-Kramer Multiple Comparisons Test 
The change in LVDP was not significant amongst groups in the recovery phase.(Fig 
6-7) The left ventricular developed pressures (L VDP) for the stabilization phase of 
the three groups were: 84.8±1 .6, 84.3±1 .0 and 86.7±1 .9 mmHg for control, hearts 
with S1 P in AHF phase and hearts with S1 P in recovery phase respectively. After 35' 
of AHF and 30' of recovery phase, control hearts had a recovery LVDP of 
39.9±23.1mmHg while hearts treated with S1P in AHF phase showed LVDP of 
49.0±16.9mmHg. The hearts that were treated with S1P in the recovery phase 




Effect of 51P in model 2 of AHF on rate pressure product 
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Stabzn Stabzn Stabzn Recovery Recovery Recovery 
Con SlPin SlPin Con SlPin SlPin 
AHF Rec AHF Rec 
Figure 6-8: Effect of S1P on RPP in model 2. (Stabzn- Stabilization phase; Rec- Recovery 
phase; S1P- sphingosine 1 phosphate; Con- Control); ns- no significance between different 
groups in recovery phase; Tukey-Kramer Multiple Comparisons Test 
Rate pressure products (RPP) for the three groups in the stabilization phase were: 
30597±3488 for controls, 26656±2384 for hearts that were then treated with 81 P in 
the AHF phase and 27134±1807 for hearts that were treated with 81 P in the 
recovery phase. (Fig 6-8) 
The recovery RPP for these groups were: 5603±2901 for controls; 5125±1611 for 
hearts after treatment with 81P in AHF phase and 9979±1765 for hearts treated with 
81 P in recovery phase. There were no significant differences between groups in the 
recovery phase. One of the control hearts and one of the 81 P in AHF hearts had 
zero recovery and hence all hearts done on that day were excluded from the study. 
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Table 6~2: Effect of S1 P treatment in AHF and recovery phase on systolic, diastolic 
pressures and coronar{ flow 
Systolic pressure (mmHg) ~ 







! Diastolic Pressure (mmHg) 
I----___~------------~---------~-~-------~ r I Control S1P in AHF I S1P in Rec 
6.5±1.Bi Stabilization I 0.0±1.5 3.B±1.7 
----------+---------------+------------1 
45.6±7.27B.7±23.7 63.9±14.1~covery I 
I I Control 
Coronary flow (ml) 
S1P in AHF 
---------j-+- S1P in Rec.---J 
IStabilization i 9.5±0.5 B.5±0.2 ! 9.2±0.4 I 
! Recovery +1---:-10-.-:-6±-0=-.6----I­ 10.3±0.3 11.0±0.3 1 
Summary 
These data suggest that S1 P administered in AHF had significantly low recovery 
versus S1P administered in recovery phase when tested in model 2. These 
experiments indicate that S1 P improved functional recovery by improving heart rate 
only but not contractility. We chose to investigate the role of the SAFE pathway in 
this protection by S 1 P. 
RESULTS 
To examine the involvement of SAFE in AHF by comparing heart rate 
Our data showed that the addition of AG490 to S1 P-induced protection abolished the 
cardioprotective effect of SAFE pathway. (Fig 6-9) The control, S1P, AG490 and 
S1 P+AG490 hearts had baseline stabilization HR values of 311.1±11.1, 304.1±13.9, 
310.7±20.7 and 271.1±11.B BPM respectively. After 30' recovery phase, control 
hearts exhibited HR of 37.9±9.7 BPM while those treated with S1P had a recovery 
128 

HR of 148.8±26.4. AG490 treatment showed a recovery HR of 117.3±50.4. However, 
a combination of S1 P and AG490 had a significantly reduced HR of 42.3±17.1. This 
shows that the add ition of AG490 to S1 P induced protection abolished the 
cardioprotective effect of SAFE pathway. 
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Con SIP AG490 SlP+AG Con SIP AG490 SlP+AG 
Stab Stab Stab 490 Rec Rec Rec 490 Rec 
Stab 
Figure 6-9: Effect of S1 P, AG490 and S1P+AG490 on HR. (Stab - Stabilization phase; Rec­
Recovery phase; S1P- sphingosine 1 phosphate; Con- Control); $$- p<O.01 vs Con Rec; #­
p<O.05 vs S1P+AG490 Rec; Tukey-Kramer Multiple Comparisons Test 
To examine the involvement of SAFE in AHF by comparing left ventricular 
developed pressure 
Left ventricular developed pressure in the stabilization phase of the 4 groups was 
84.9±2.0, 87.1±1 .1. 89.7±2.4 and 89.0±2.8 for control . S1P, AG490 and S1P+AG490 
hearts respectively. (Fig 6-10) The recovery values after 35' of AHF and 30' of 
recovery phase were: 30.4±12.6. 55.6±7.7, 22 .3±9.0 and 52.3±21 .1 mmHg 
respectively for control, S1 P, AG490 and S1 P+AG490. There was no statistical 























Con SlP AG490 SlP+AG Con SlP AG490 SlP+AG 
Rec 490 RecStab Stab Stab 490 Rec Rec 
Stab 
Figure 6-10: Effect of S1P, AG490 and S1P+AG490 on LVDP. (Stab -Stabilization phase; 
Rec- Recovery phase; S1 P- sphingosine 1 phosphate; Con- Control); ns- not significant 
between groups; Tukey-Kramer Multiple Comparisons Test 
To examine the involvement of SAFE in AHF by comparing rate pressure 
product 
Rate pressure product for the different groups in stabilization phase was 
26433±1112, 26508±1273, 27752±1604 and 24013±535 for control, S1 P, AG490 
and S1 P+AG490 respectively. (Fig 6-11) At the end of the recovery phase, these 
groups had RPP values of 1941±987, 8461±1350, 3975±1832 and 2871±1268 for 
control, S1 P, AG490 and S1 P+AG490 respectively. Statistically, there was no 





















Con SI P AG490 SIP+AG Con SIP AG490 SlP+AG 
Stab Stab Stab 490 Rec Rec Rec 490 Rec 
Stab 
Figure 6-11: Effect of S1P, AG490 and S1P+AG490 on RPP. (Stab- Stabilization phase; 
Rec- Recovery phase; S1P- sphingosine 1 phosphate; Con- Control); ##- p<O.01 vs Con 
Rec; ns- not significant vs S1P+AG490 Rec; Tukey-Kramer Multiple Comparisons Test 
Table 6-3: Effect of 81 P, AG490 and 81 P+AG490 treatment on systolic, diastolic 
pressures and corona ry flow 
Systolic pressure (mmHg) 
Control S1P AG490 S1P+AG490 
Stabilization 88.7±2.6 89.8±2.0 92.2±3.1 94.3±2.5 
Recovery 96.5±16.5 100.2±7.6 110.1±9.6 105.7±17.6 
Diastolic Pressure (mmHg) 
Control S1P AG490 S1P+AG490 
Stabilization 3.7±1.41RR1' 2.6±1 .81RR1' 2.5±2.91RR1' 5.3±2.11R1 
Recovery 66.0±12.7 44.5±5.1** 87.7±10.5 53.4±9.8 
Coronary flow (ml) 
Control S1P AG490 S1P+AG490 
Stabilization 8.7±0.2 9.0±0.2 8.6±0.3 9.1±0.3 
Recovery 10.9±0.3 10.9±0.3 10.1 ±0.3 11.0±0.6 
Table 6-3: ###- p<O.001 vs. Respective recovery groups; ##- p<O.01 vs. Respective 
recovery group; **- p<O.01 vs. AG490 recovery 
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The stabilization phase diastolic pressures were significantly increased in recovery 
phase for all groups (###- p<O.001 and ##- p<O.01 vs. S1 P+AG490 rec). Treatment 
with S1 P had a significantly lower (p<O.01) diastolic pressure as compared to AG490 
in the recovery phase. (Table 6-3) 
Summary 
Our data suggest that the protective action of S1 P was indeed abrogated by the 
addition of the Janus kinase inhibitor, AG490. These are preliminary data that 
suggests that the SAFE pathway might be involved in the cardioprotective 
mechanism of S1 P against de novo acute heart failure . 
RESULTS 
Western blots for determination of STAT3 in AHF: 
We measure the expression of phosphorylated STAT3 when it was bound to its 
tyrosine residue and serine residue. We saw expression of STAT3 when it was 
bound to its serine residue only. We did not see any expression of phosphorylated 
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Figure 6-12: Phosphoser STAT3 and Total STAT3 in mitochondrial fraction 
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Figure 6-13: Ratio of p-ser STA T3/ total STA T3 in mitochondrial fraction 
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Figure 6-14: Western blots for STAT3 in the mitochondrial fraction 
In the mitochondrial fraction of the hearts subjected to AHF and 7' recovery, there 
was no significant difference in the amount of phosphor-ser STAT3. This suggests 
that the phosphorylated STAT3 was not translocated to the mitochondria. 
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Figure 6-15: Phosphoser STAT3 and Total STAT3 in cytosolic fraction 













Figure 6-16: Ratio ofp-ser STAT31 total STAT3 in cytosolic fraction 
control AG 490 SIP AG490 + 
SIP 
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Figure 6-17: Western blots for STAT3 in the cytosolic fraction 
Observing the cytosolic fraction , S1 P increased phosphor-ser STAT3 when 
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Figure 6-18: Phosphoser STA T3 and Total STA T3 in nuclear fraction 
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Figure 6-19: Ratio of p-ser STA T3/ total STA T3 in nuclear fraction 
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Figure 6-20: Western blots for STA T3 in the nuclear fraction 
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In the nuclear fraction , we observed significant increase in phosphorylation of 8TAT3 
when compared vs. controls thus suggesting that the activity of phosphorylated 
8TAT3 was via the serine residue and mediated in the nucleus. 
Summary 
The Western blots for 8TA T3 suggest that after AH F, treatment with 81 P increases 
the amount of activated 8TAT3 in the nucleus which might contribute to the 
protective effect of 81 P. 
RESULTS 
Effect of 51 P on cell death 
Expression of cytochrome C (CytC) was analysed in hearts subjected to AHF. The 
protein quantification was done using Lowry's method126 as previously described 
and subseCl.uently the gels were run and probed for CytC . Treatment with 81 P 
significantly reduced the expression of Cyt C after AHF as did AG490. Cell death 
was measured by Western blotting for expression of CytC. 
' ,r, Y r ' , _ ..~}"~ ,;( '1 























Control AG490 SlP SlP+AG490 
Tukey- Kra m er Multiple Com pari son Test 
• . p <O.O S V5 AG4 9 0; '" p <O.OS vs S 1 P 
Figure 6-21: Effect of pharmacological treatment on expression of cytochrome C 
Reduction of CytC expression by treatment with S1 P was not abrogated by the 
addition of AG490 , suggesting that this protection was not via the SAFE pathway. 
The same endpoints as the ones described above were monitored for these 
experiments. The glucose concentration in the stabilization phase was 11.1 mmol/L 
with no fatty acids in the perfusate, the AHF and recovery phase saw reduced 
glucose (2.5mmoI/L) and high fatty acids (1 .3mmoI/L) in the perfusate . 
o·l " ''':­. . ; ,.... 
RESULTS 
Effect of ranolazine administration in the AHF phase 
Isolated hearts were perfused with ranolazine in the AHF phase in the absence of 
adrenaline (model 1). Besides the reduction of perfusion pressure, glucose 
concentration in the perfusate was lowered to 2.5mmol/L and FFA (1.3mmoI/L) was 
introduced in this phase. 
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Control Ranolazine Control Ranolazine 
Stabzn Stabzn Rec Rec 
Figure 6-22: Effect of ranolazine on HR in model 1. (Stabzn- Stabilization phase; Rec­
Recovery phase); ns- not significant vs. control rec; Tukey- Kramer Multiple Comparison 
Test . 
There was no significant change in the heart rate after treatment with ranolazine . 
After 30 minutes of stabilization phase, control hearts had a mean HR of 291.9±13.7 
BPM and ranolazine hearts had a mean HR of 296.0±15.2 BPM. (Fig 6-22) However, 
the recovery HR in hearts without ranolazine treatment was 140.2±36.5 and those 
that were treated with ranolazine had a heart rate of 134.5±50.3 BPM. 
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Stabzn Stabzn Rec Rec 
Figure 6-23: Effect of ranolazine on LVOP in model 1. (Stabzn- Stabilization phase,' Rec­
Recovery phase); ns- not significant vs. control rec; Tukey- Kramer Multiple Comparison 
Test 
Treatment with ranolazine in the AHF phase had no significant improvement in LVDP 
of these hearts. (Fig 6-23) The left ventricular developed pressures (LVDP) for 
control and ranolazine hearts in the stabilization phase were : 90.4±2.5 and 84.9±O.8 . 
mmHg. However, hearts without ranolazine treatment had a LVDP of 51.0±12.5 
mmHg while those with ranolazine treatment in the AHF phase had 57.2±6.9 mmHg. 
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Control Ranolazine Control Ranolazine 
Stabzn Stabzn Rec Rec 
Figure 6-24: Effect of ranolazine on RPP in model 1. (Stabzn- Stabilization phase; Rec­
Recovery phase); ns- not significant vs . control rec; Tukey- Kramer Multiple Comparison 
Test 
The treatment with ranolazine had no effect on RPP. Rate pressure products (RPP) 
at the end of stabilization for control and ranolazine groups were 26409±1479 and 
25180±1471 respectively. (Fig 6-24) Hearts that were not treated with ranolazine had 




Table 6-4: Effect of ranolazine treatment on systolic pressure, diastolic pressure and 
coronary flow 
Systolic pressure (mmHg) 
Control 	 RanolazineI 
i Stabilization 91.4±2.4 	 84.3±O.3I 
.~.---..• -	 -. 
tRecOVery 63.9±12.8 	 95.4±7.9*I 	 I 
Diastolic Pressure (mmHg) 
Control 	 Ranolazine 
-. 
i Stabilization O.9±O.4 O.O±O.6 












Table 6-4: *- p<O.05 V~l. Control; **. p<O.01 vs Controls 
Ranolazine increased systolic pressure significantly (p<O.05 vs. controls) but had 
worse diastolic pressure recovery. The treatment with ranolazine in the AHF phase 
did not improve relaxation in the recovery phase which was significantly higher as 
compared to controls (p<O.01 )(Table 6-4) 
Summary 
These data showed no statistical significance as we did not see any improvement 
with ranolazine when used as a cardioprotective agent in the AHF phase. Hence, we 





1. Cardioprotection by sphingosine-1-phosphate 
Treatment with S1 P administered in the AHF phase increased the heart rate, but not 
the contractility. When S1 P was administered in the absence of adrenaline, it was 
cardioprotective. There was, however, no improvement in systolic pressures in the 
treated hearts. S1 P treatment did not reduce diastolic pressure, indicating impaired 
relaxation. However, In the presence of adrenaline, S1 P had no effect when tested in 
the AHF phase but improved heart rate when administered in the recovery phase. 
These data suggest that cardioprotection by S1 P is via the increased activity of the 
sinus node. S1 P asserts its activity in the heart by either binding to one of the three 
receptors or as an intracellular agent, however there is no published data for the 
latter.83 The three S1P receptors in the heart i.e. S1P1, S1P2 and S1P3, are involved 
in myocyte survival, inflammation pathways, vascular resistance and heart rate either 
individually or in conjugation. In experiments by Sanna et af7, examining the effects 
of various S1 Preceptors, S1 Preceptor 3 was shown to be responsible to control 
sinus rhythm. 
2. Mechanisms involved in cardioprotection by 51 P 
The Reperfusion Injury Salvage Kinase (RISK) 134 and Survivor Activating Factor 
Enhancement (SAFE)48,135 pathways are the main pro-survival pathways discovered 
in the heart which protect from lethal reperfusion injury. S1 P is a preconditioning 
agent which reduces Infarct size and improves functional recovery after an ischaemic 
insult. The action of S1 P against ischaemic-reperfusion injury involves the partial 
activation of the RISK pathway.102,104,136 S1 P acts as a mediator between both RISK 
and SAFE pathways when administered at the onset of reperfusion in the ischaemia-
reperfusion model. In studies by Somers et a/102 cardioprotection by S1 P was 
abrogated both in the presence of inhibitors of SAFE and RISK pathways suggesting 
that cardioprotection via S 1 P acts as a mediator between the two pathways. Both 
SAFE and RISK pathways deactivate FOXO-1 which is an important mediator in the 
apoptosis cascade. 1o;J Our data suggests that the SAFE pathway is involved in the 
cardioprotective effect of S 1 P as we find up-regulation of ST AT3 in the nuclear 
fraction of the cells. In our model, we propose that the activation of STAT3 by virtue 
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of S1P binding to its G- protein coupled receptors (GPCR's) causes STAT3 to 
translocate to the nucleus where the phospho-serine residue dimerises and initiates 
survival in the form of inactivation of pro-apoptotic factors or the propagation and 
expression of proteins that are involved in cardioprotection (such as BCI, VEGF and 
others). We collectec the tissue from the hearts at seven minutes into the recovery 
phase in the same manner as did Somers et al. 102 They studied the role of S1 P 
induced cardioprotec:tion in the SAFE and RISK pathways using isolated mouse 
hearts to induce a gobal ischaemia on a Langendorff perfusion system and found 
different amounts of phosphorylated ST AT3 in mitochondria and cytosolic fractions 
when hearts were harvested at seven minutes and fifteen minutes. At seven 
minutes, they observed that phosphorylated ST AT3 was significantly increased in 
the mitochondria, but this was reduced when hearts were harvested at fifteen 
minutes of reperfusion. In the SAFE pathway, STAT3 is first phosphorylated at the 
tyrosine residue which then dimerises and translocates to the nucleus, where it is 
phosphorylated again at the serine residue and then activates survival pathways.48 
In our experiments to evaluate the effect of STAT3 in AHF, despite multiple attempts, 
we did not see any ST AT3 expression in our phospho-tyrosine residue of ST AT3. 
However, after treatment with S1 P and harvesting the hearts at seven minutes into 
the recovery phase, we saw significant elevation of the phospho-serine residue of 
STAT3, which suggests that STAT3 might be translocated directly to the nucleus and 
that the phosphorylation on the serine residue might be the key to induce its 
protective effect. We speculate that this increase in phosphorylated STAT3 is a time 
dependent outcome similar to that found by Somers et al. 102 We anticipate that 
further experiments at different time points will help elucidate the mechanism of 
cardioprotection by STAT3 and its various cellular fractions. 
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IMPROVED SINUS RHYTHM; 
t FUNCTIONAL RECOVERY 
Figure6-25: Proposed scheme for cardioprotective effect of S1 P by activation of SAFE 
pathway. (adapted from Lecour S. 2009)48(S1P- sphingosine-1-phosphate; JAK- Janus 
kinase; STA T3- signa' transducer and activator of transcription 3) 
3. S1P and cell death 
S1 P was protective against cell death in our experiments. It significantly reduced the 
expression of cytochrome C in hearts subjected to de novo acute heart failure. We 
speculate about the effect of the SAFE pathway in the protection against cell death 
in our model. The hearts treated with AG490 also showed reduced cell death, which 
also suggests that the protective effect of S1 P in AHF is mediated via the nucleus. 
Cytochrome C is involved in the early stages of the pro-apoptotic pathway and we 
propose that inhibition of molecules like caspases would provide more conclusive 
proof of S1 p's anti-apoptotic properties. 
4. Ranolazine 
Treatment with ranolazine did not show any significant improvement in our model of 
heart failure. Ranolazine acts by reducing the cellular acetyl-CoA quantities by 
inhibiting the J3-mddation of fatty acids and activation of pyruvate 
dehydrogenase. 137,138 In our experiments with ranolazine, when ranolazine was 
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administered in the AHF phase of the mild model, it did not improve the functional 
recovery. It did, however; improve the systolic pressure when compared to control 
hearts. Besides increasing systolic pressure, hearts treated with ranolazine also had 
elevated diastolic pressures, indicating impaired relaxation. 
One possible drawback of our experiments that might contribute to the failure of 
ranolazine in this model might be the low concentration of glucose in the perfusate. 
We used 2.5mmoliL of glucose in the perfusate which is pathologically low. 
Ranolazine promotes glucose oxidation by partially inhibiting fatty acid oxidation and 
most likely needs physiological or higher levels of glucose to exert its 
cardioprotective effects. 
CONCLUSION 
Treatment with S1 P when administered in the AHF phase in the absence of 
adrenaline (model 1) greatly improves the heart rate. However, there was no change 
in the contractility of the heart. 
In the presence of adrenaline (model 2), S1 P treatment in the AHF phase had no 
significant improvement on the functional recovery, but S1 P administered in the 
recovery phase improved the heart rate only. 
This protection by S1 P is mediated by the Survivor Activating Factor Enhancement 
(SAFE) pathway and exerts its effects via the nucleus. 
In our model of de novo AHF, the low concentration of glucose in the perfusate, 









METABOLIC AGENTS FOR 

RECOVERY FOLLOWING DE 

NOVO ACUTE HEART FAILURE 

INTRODUCTION 
Our previous experiments have shown sphingosine-1-phosphate (81 P), glucose and 
insulin individually to be cardioprotective against our models of de novo acute heart 
failure. However, these agents improve functional recovery by increasing the heart 
rate only. There was no improvement in the contractility of the left ventricle. Hence, 
we hypothesized that the combination of metabolic and pharmacological agents will 
further add to the card loprotective properties of these agents and that these agents 
will improve the mitochondrial respiration following an episode of acute heart failure. 
HYPOTHESIS 
The previous experiments with metabolic and pharmacological agents individually 
improved functional recovery by increasing the heart rate. We hypothesize that the 
combination of these agents would have an additive effect in the improvement of 
functional recovery from AHF and improve the mitochondrial respiration as well (Fig. 
7-1 ) 
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ACUTE HEART FAILURE 
(AHF) 
') . 
Combination of therapy by 
metabolic and pharmacological 
agents to counter adverse effects 





Figure 7-1: Hypothesis that treatment with metabolic + pharmacological agents improves 
recovery after AHF 
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MATERIALS AND METHODS 
Animals 

As previously described in chapter 4. 

Protocols for isolated heart studies 
STABILIZATION AHF RECOVERY 
30' 35' 30' 
0' I I 
 95' 
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0' 72'I I 
7' 
100 em H2O 20 em H2O 100 em H2O 
Stabilization AHF 
11.1mmol/L 11.1mmol/L Glucose; 11.1mmol/L Glucose; 
Glucose; no FFA no FFA; (no AHF) no FFA 
Model 2 11.lmmol/L 2.Smmol/L Glucose; 11.1mmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; 10-8 1.3mmol/L FFA 
Adrenaline 
Model 2 11.1mmol/L 2.Smmol/l Glucose; 11.1mmo1/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; 10-8 1.3mmol/L FFA; 10nM 
Adrenaline SlP 
Model 2 11.1mmol/L 2.Smmol/L Glucose; 11.1mmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; 10-8 1.3mmol/L FFA; 
Adrenaline 0.3mU Insulin 
Model 2 11.lmmol/L 2.Smmol/L Glucose; 11.lmmol/L Glucose; 
Glucose; no FFA 1.3mmol/L FFA; 10-8 1.3mmol/L FFA; 10nM 
Adrenaline SlP; 
O.3mU Insulin 
Mitochondrial respi ration studies 

The hearts were harvested at 7' in the recovery phase and the mitochondria were 




























High Glucose Rec with High High Rec with High 
Stabzn Glucose Glucose+SlP Glucose + SlP 
Stabzn 
Figure 7-2: Effect of glucose + S1P on HR in model 2. (Stabzn- Stabilization phase; S1P­
sphingosine-1-phosphate; Rec: Recovery phase); ### p<O.001 vs. Rec with high glucose; # 
p<O.05 vs. Rec with high glucose+S1P; *p<O.05 vs. Rec with high glucose; Tukey- Kramer 
Multiple Comparison Test 
Treatment with S1 P and glucose significantly improved the heart rate in these hearts 
(p<0.01 vs. recovery with high glucose) . (Fig 7-2) In the stabilization phase, control 
hearts had a HR of 288.2±11.7 BPM and the HG+S1 P hearts had a stabilization HR 
of 265.8±5.8 BPM. After 30' recovery phase, hearts perfused with high glucose 
showed a HR of 92.7±28.6 BPM while those treated with high glucose+ S1 P had a 
HR of 179.7±18.2 BPM. 
Effect of high glucose + S1P on left ventricular developed pressure (LVDP) 
Addition of S1 P to glucose did not alter the LVDP at recovery. (Fig 7-3)ln the 
stabilization phase, control hearts showed LVDP of 83.1 ±2.5 mmHg while the high 
glucose+ S1 P hearts had stabilization LVDP as 95.0±5.6 mmHg. After 30' of 
recovery, control hearts had an LVDP of 73.9±18.7 mmHg while the high glucose+ 
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S1 P hearts had a recovery LVDP of 70.1 ±9.1 mmHg. It was statistically insignificant 























High Glucose Rec with High High Rec with High 
Stabzn Glucose Glucose+SlP Glucose + SlP 
Stabzn 
Figure 7-3: Effect of glucose + S 1 P on LVDP. (Stabzn- Stabilization phase; S1P­
sphingosine-1-phosphate; Rec: Recovery phase); ns- not significant vs. Rec with high 
glucose; Tukey- Kramer Multiple Comparison Test 
Effect of high .glucose + S1P on rate pressure product (RPP) 
The stabilization values of RPP of control and HG+S1 P hearts were 23903±870 and 
25272±1625 respectively. (Fig 7-4) Treatment with high glucose (in the recovery 
phase) alone had a recovery RPP of 6762±2084 while the combination of S1 P and 
high glucose had a recovery RPP of 13153±2436. The stabilization phase values of 
both groups were very significant vs. their respective recovery groups (p<0.001) . 
However, treatment with high glucose plus S1 P had no significant improvement in 



























High Glucose Rec with High High Rec with High 
Stabzn Glucose Glucose+SIP Glucose + SIP 
Stabzn 
Figure 7-4: Effect of glucose + S1 P on RPP, (Stabzn- Stabilization phase; S1 P­
. sphingosine-1-phosphate; Rec: Recovery phase); ### p<O.001 vs. respective recovery 
groups; ns- not significant vs. Rec with high glucose; Tukey- Kramer Multiple Comparison 
Test 
Table 7-1: Effect of high glucose+ S1 P on systolic and diastolic pressures and 
coronary flow in model 2: 
Systolic pressure (rnmHg) 
High glucose High glucose + S1 P 
Stabilization 89 ,O±2.1 96.7±5.8 
Recovery 85.8±18.8 77,8±9.8 
Diastolic Pressure (mmHg) 
High glucose High glucose + S1 P 
Stabilization 5.9±1 .6 1.6±1 .2 
Recovery 11.9±3.8 7.6±3.0 
Coronary flow (ml) 
High glucose High glucose + S1 P 
Stabilization 9.1 ±O.2 8.8±O.3 
Recovery 10.8±O.2** 10.5±O.3** 
Table 7-1: **- p<O.01vs. Respective stabilization values 
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There were no statistical differences between groups in systolic and diastolic 
pressures. However, both groups had significantly (p<0.01) higher coronary flow 
rates in the recovery phase vs . respective stabilization phases. (Table 7-1) 
Summary 
A combination of high glucose and sphingosine-1-phosphate improved the functional 
recovery of the hearts after an episode of severe de novo acute heart failure on our 
system. This recovery was only due to the improvement in the heart rate. There was 
no significant improvement in the contractility of the heart as showed by the 
insignificant improvement in the left ventricular developed pressure. 
RESULTS 
Effect of combination of metabolic+ pharmacological treatment on heart rate: 
350 
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Stabzn Rec Stabzn Rec Stabl" Rec Stabzn Rec 
High High High High 
glucose glucose glucose+ glucose+ 
+ S1P insulin S1 P+ insulin 
Figure 7-5: Effect of glucose+ insulin + S1P on HR. (Stabzn- Stabilization phase; S1P­
sphingosine-1-phosphate; Rec: Recovery phase); ***- p<O.001 vs. High glucose in recovery 
phase; Tukey- Kramer Multiple Comparison Test 
Treatment with metabolic agents glucose and insulin as well as molecular agent S1 P 
increased the heart rate significantly vs. hearts treated with glucose only. (Fig 7-5) 
Stabilization HR for high glucose (HG), HG+S1 P, HG+ insulin and HG+S1 P+insulin 
hearts was 272.210.5, 340.8±11.3, 303.4±14.1 and 314.8±17.0 BPM respectively ; 
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HG plus insulin had a recovery HR of 223.4±27.6; HG+S1 P had a recovery HR of 
214.S±30.7; HG+S1 P+lnsulin had a recovery HR of 214.4±19.2; HG hearts had a 
recovery HR of 66.S±22.6 BPM . 
Effect of combination of metabolic+ pharmacological treatment on left 



























Stabzn Rec Stabzn Rec 
0
Stabzn Rec Stabzn Ret 
High High High High 
glucose glucose glucose+ glucose+ 
+ S1P insulin S1P+ insulin 
Figure 7-6: Effect of g/ucose+ insulin + S1 P on LVDP. (Stabzn- Stabilization phase; S1P­
sphingosine-1-phosphate; Rec: Recovery phase); ***- p<O.001 vs. al/ groups in recovery 
phase; Tukey- Kramer Multiple Comparison Test 
The combination of metabolic and molecular agents had a significant improvement 
vs. all groups, displaying improved contractility of the hearts. (Fig 7-6)Stabilization 
LVDP values for HG, HG+S1P, HG+ insulin and HG+S1P+ insulin were 83.2±1 .2, 
83.8±O.6, 86.3±1.2 and 91.6±2.4 mmHg respectively . Treatment with HG+lnsulin had 
a recovery LVDP of 42.S±8.S; HG+S'IP had a recovery LVDP of 66.S±2.2; 
HG+S1 P+lnsulin treatment had a recovery LVDP of 177.2±38.6mmHg which was 
significant over all other groups in the recovery phase (p<O.001); HG hearts 





Effect of combination of metabolic+ pharmacological treatment on rate 


















Stabln Rec Stabln Rec Stabzn Rec Stabln Rec 
High High High High 
glucose glucose glucose+ glucose+ 
+ S1P insulin S1 P+ insulin 
Figure 7-7: Effect of glucose+ insulin + S1 P on RPP. (Stabzn- Stabilization phase; S1P­
sphingosine-1-phosphate; Rec: Recovery phase); ** *- p<O.001 vs. al/ groups in recovery 
phase; Tukey- Kramer Multiple Comparison Test 
The improvement in heart rate and LV developed pressure significantly improved the 
rate pressure product (p<0.001) in the hearts treated with the combination of 
molecular and metabolic agents when compared against all groups. (Fig 7­
7)Stabilization values of RPP were 22651 ±796 for HG, 28605±1139 for HG+S1 P, 
26167±2226 for HG+ insulin and 28880±1795 for HG+ S1 P + insulin; In the recovery 
phase, treatment with HG+ insulin had a RPP of 9263±2226; and HG+S1 P had a 
recovery RPP of 14003±1742; while HG+S1 P+lnsulin improved recovery to 
40568±11054 which was significant over all other groups in the recovery phase 




Table 7-2: Effect of combination of metabolic+ pharmacological treatment on 
systolic, diastolic pressures and coronary flow in model 2: 
Systolic pressure (mmHg) 
High glucose High 
glucose + 
S1P 
High glucose + 
insulin 
High glucose + 
S1 P + insulin 
Stab i Iizati0 n 92.9±1.2 92.5±O.6 96.5±1.5 96.8±3.0 
Recovery 69.3±11.0 97.3±4.6 99.1±2.6 251.7±39.0*** 
Diastolic Pressure (mmHg) 
High glucose High 
glucose + 
S1P 
High glucose + 
insulin 
High glucose + 
S1P + insulin 
Stabilization 9.5±1.0 8.8±1 .0 10.1±O.3 5.1 ±2.2 
Recovery 48.8±13.5* 30.8±5.1 56.6±9.6** 74.5±13.6***/" 
Coronary flow (ml) 
High glucose High 
glucose + 
S1P 
High glucose + 
insulin 
High glucose + 
S1 P + insulin 
Stabilization 9. 1±O.3 9.4±O.2 8.9±O.3 9.1 ±O.4 
Recovery 10.6±O.2 12±O.4** 10.5±O.5 10.6±O.3 
Table 7-2: ***. p<O.001 vs. all recovery groups in systolic pressure; *. p<O.05 vs. High 
glucose stabilization diastolic pressure; **. p<O.01 vs. HG+insulin stabilization diastolic 
pressures; ***- p<O.001 vs. HG+insulin+ S1P stabilization diastolic pressure; ## p<O.01 vs. 
HG+ Insulin recovery diastolic pressure; **. p<O.01 vs. HG+S1 P stabilization coronary flow. 
The combined treatment with pharmacological and metabolic agents significantly 
increased systolic pressure (p<O.001) in the recovery phase as compared to all other 
groups in the recovery phase. (Table 7-2) This treatment also increased diastolic 
pressures in the recovery groups when compared to HG+S1 P alone. All diastolic 




om OS Time 
stabilization values (p<O.05 vs HG stabilization; p<O.01 vs. stabilization with HG+ 
insulin and p<O.001 vs. HG+ S1 P+ insulin). Comparing the coronary flow, only 
HG+S1 P in recovery phase had a significantly (p<O.01) higher flow as compared to 
its stabilization phase. 
Summary 
The combination of metabolic and pharmacological agents not only improved heart 
rate, but LVDP also. The improvement in LVDP has not been seen in any of the 
other experiments where only either metabolic or pharmacological agents were 
used. Also, the decrease in LVEDP was seen when high glucose was combined with 
S1 P. Hence, we conclude suggesting that a combination of metabolic and 
pharmacological therapy is essential in the treatment of AHF. 
RESULTS 
Mitochondrial respiration studies 
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Figure7-8: Example of a trace on the Clarke type electrode measuring mitochondrial 
respiration 
158 
State2 respiration comparison 
.... 15tio 
E 
nsns ns.... nsc 
'E 
















Baseline Control SiP Insulin SlP+lnsulin 
Controls. 
noAHF 
Figure 7-9: Effect of metabolic and pharmacological agents on State2 respiration; ns- not 
significant between groups and VS . baseline controls; Bonferroni Multiple Comparisons Test 
Baseline controls (no AHF) showed a state2 respiration of 13.6±1.9 nmoI02.min­
1.mg-1; Control hearts (AHF) showed state2 respiration values of 10.3±1.4 
nmoI02.min-1.mg-1; hearts treated with S 1 P had a state2 respiration value of 
10.8±O.9 nmoI02.min-1.mg-1; hearts treated with Insulin had a state2 respiration value 
of 10.7±1 .2 nmoI02.min-1.mg-1 ; while hearts with HG+S1 P+lnsulin had a state2 
respiration value of 1 O.9±O. 7 nmoI02.min-1.mg-1 
No significance amongst groups was observed suggesting that there was no change 
in the ability of the mitochondria to utilize substrate. (Fig 7-9) 
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Figure 7-10: Effect of metabolic and pharmacological agents on State3 respiration; ns- not 
significant between groups and vs. baseline controls; Bonferroni Multiple Comparisons Test 
Baseline controls (no AHF) had a state3 respiration value of 59.1 ±1B.9 nmoI02.min­
1.mg-1; Controls (with AHF) had a state3 value of 4B .6±9.3 nmoI02.min-l.mg-l; hearts 
treated with S1 P had a state3 respiration value of 51.9±2.B nmoI02.min-l .mg-l ; 
Insulin treated hearts had a state3 respiration value of 53.1±7.0 nmoI02.min-l.mg-l; 
After the S1 P+lnsulin treatment, the observed state3 respiration values were 
41.5±7.2 nmoI02.min-l .mg-l 
No statistical significance was observed between groups suggesting that the rate of 
conversation of ATP to ADP was insignificant between groups. (Fig 7-10) 
Respiratory control index (Rei) comparison 
Baseline controls had an RCI of 4.9±0.3 AU; controls with AHF had an RCI of 
5.0±0.5 AU; S1 P treatment increased RCI to 6.2±0.5 AU; Insulin treatment had an 
RCI of 5.1±03 AUand S1 P+lnsulin had an RCI of 4.1±0.6 AU. There was no 
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Figure 7-11: Effect of metabolic and pharmacological agents on RCI; ns- not significant 
between groups and VS. baseline controls; Bonferroni Multiple Comparisons Test 
DISCUSSION 
1. Outcome of functional recovery: 
In our previous experiments, treatment with either metabolic or pharmacological 
agents displayed improved recovery only due to the increase of heart rate. The 
recovery in contractility in those experiments was very poor. The failing heart not 
only has a compromised heart rate, but also compromised contractility. In the 
previous experiments, treatment with glucose and insulin significantly reduced the 
diastolic pressure, indicating improved relaxation. The aim of experiments in this 
chapter was to examine if the combination of metabolic and molecular agents not 
only improve the heart rate, but the contractility also. 
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When S1P was combined with glucose, the effect was seen on only heart rate 
meaning that this effect was also mediated by the sinus node, as seen previously. 
However, when S1P was coupled with glucose and insulin, it improved HR as well as 
L VDP. We propose the following explanation for this effect: 
S 1 P has a metaboliG effect where it promotes the uptake of glucose by insulin. In 
experiments done in pancreatic beta cells, exposure to high glucose up-regulated 
the activity of sphingosine kinase which increased S1 P levels and that stimulated the 
secretion of insulin.9~ When insulin and glucose were perfused in the recovery phase 
of our previous experiments, the resultant effect was observed on the heart rate only. 
However, with the addition of S1 P to this combination of glucose and insulin, we 
propose that S1 P promotes glucose metabolism by inhibiting fatty acid oxidation in 
these hearts. 
Another explanation of this increase of L VDP might be the effect of insulin as a 
pharmacological agBnt. Insulin is one of the activators of the SAFE pathway and 
promotes survival. We propose that the combination of S1 P and insulin also 
stimulates the SAFE. pathway and the phosphorylation of ST AT3 takes place in the 
nucleus which elucidates protection. These experiments possibly display interplay of 
activities of S1 P and insulin, but more work is needed to confirm this hypothesis. 
2. Effect of metabolic and pharmacological therapy on mitochondrial 
respiration: 
The combination of these agents had no effect on the mitochondrial respiration when 
hearts were harvested from the Langendorff apparatus at 7' into the recovery phase. 
We used this time point to extract mitochondria because at 7' Somers et a/102 saw 
elevated phosphorylation of STA T3. We failed to see any change in the 
phosphorylated STAT3 contents when treated with S1 P and similarly, when a 
combination was tested, we did not see a difference in mitochondrial respiration. 
This also indicates that the protective pathway involved in AHF is the SAFE pathway 
but this does not involve the mitochondria to exert its effect. This pathway is 
mediated via the nucleus since we observed the elevated levels of phosphorylated 
STAT3 in the nuclear fraction at 7'. 
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CONCLUSION 
The combination of glucose and S1 P administered in the recovery phase of model 2 
(AHF with adrenaline) increased the heart rate but not the contractility. However, the 
combination of S1 P, insulin and glucose administered in the recovery phase (of 
model 2) not only increased heart rate, but also LV developed pressure. 
The combination of metabolic and pharmacological agents did not have a statistically 
significant effect on the mitochondrial respiration. The individual agents also had no 






The experiments in this thesis describe data obtained with a new inexpensive 
isolated heart model of de novo acute heart failure (AHF). This model is easily 
reproducible, simple to perform and allows us to study the effect of acute heart 
failure (AHF) on thl3 heart in isolation. To our knowledge, this is the first ex-vivo 
model of AHF uSing isolated rat hearts perfused in a modified Langendorff 
retrograde system. We tested both the metabolic agents glucose and insulin and the 
molecular agent sphingosine-1-phosphate (S1P) as therapeutic agents on two 
different experimental groups, all with AHF. 
• Model 1 where AHF was induced by hypotension and substrate changes only, 
no adrenaline was added and 
• Model 2 where AHF was characterized by substrate changes along with 
adrenaline and reduced perfusion pressure. 
The two models were used to determine functional recovery and cell death by 
apoptosis by measuring the expression of cytochrome C. S1 P is cardioprotective in 
ischaemic-reperfuslon injury and reduces infarct size.74,84, 102, 139, 140 Provision of 
glucose is protective to the metabolically threatened cell because glucose generates 
membrane protective ATP both via glycolysis and Krebs cycle activiti 41 that 
counters stress situations such as AHF. 
In model 1, glucose in the recovery phase improved heart rate and reduced diastolic 
pressure, hence improving recovery. S1 P administered in the AHF phase also 
increased heart rate but not the contractility. 
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In model 2, addition of adrenaline, which mimics the adrenergic stimulus associated 
with AHF, abrogated the effect of glucose alone. However, heart rate increased and 
diastolic pressure was reduced when insulin was added in combination with glucose. 
In other experiments, provision of glucose in the AHF phase with adrenaline also 
improved recovery. There was no effect on expression of cytochrome C after 
treatment with glucose and insulin. 
Treatment with S1 P in the recovery phase of model 2 also increased heart rate but 
had no effect on contractility. This improvement in function by S1 P is mediated via 
the survivor activating factor enhancement (SAFE) pathway which involves the 
activation of signal transducer and activator of transcription factor 3 (STAT3) (Fig 8­
1). STAT3 phosphorylation was significantly up-regulated in the nucleus. Treatment 
with S1 P also significantly reduced the expression of cytochrome C which is a 
marker for apoptosis. 
SIP 1 









IMPROVED SINUS RHYTHM; 
t FUNCTIONAL RECOVERY 
Figure 8-1: Schematic of the SAFE pathway (adapted from Lecour S) 48. SAFE pathway is 
activated byS1 P receptors which in turn activate the Janus kinases which on 
phosphorylation activate signal transducers and activators of transcription 3 (STA T3) 
molecules. The STA T3 molecules dimerize and translocate to the nucleus thereby activating 
the pro-survival pathway. STA T3 belongs to a family of transcription factors which are 
capable of forming homo and heterodimers which influence gene transcription in the 
nucleus. (SAFE- Survivor Activating Factor Enhancement pathway; JAK- Janus kinase; 
ST A T3- signal transducer and activator of transcription 3,' TNF- tumor necrosis factor) 
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When both pharmacological and metabolic agents were used in combination, 
glucose+insulin+ S'I P not only increased heart rate, but contractility also. There was, 
however, no change in mitochondrial respiration. The expression of phosphorylated 
STAT3 was elevated significantly in the nucleus, suggesting that the SAFE pathway 
is involved and exerts its protective effects via the nucleus. The increase in heart 
rate in all our experiments with pharmacological and metabolic agents suggests that 
these agents work on the sinus node and improve sinus rhythm, hence improving 
recovery. 
Phase 1: 
Validation of an acute heart failure 
(AHF) model using isolated rat hearts 
Phase 2: ModelofAHF 
Metabolic Pharmacological 
.treatment viatreatment 
Metabolic~ SAFE pathway ~ ~ ~ i ... . ", " . 
. ':; ~.It , . ~ , ~ ~ " ;, ,,Pharmar.olog~c 
al trealtmen~ 
IMPROVED RECOVERY, REDUCED CEll DEATH 
Figure 8-2: Treatment with either metabolic or pharmacological or a combination of the two 
improves recovery after AHF 
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Limitations of this study 
The first and most important limitation of our study is the use of isolated hearts. 
Despite the advanta~Jes of isolated heart preparations, the separation of hearts from 
the body is non-physiological. Heart failure is a systemic disease and a failing heart 
is the outcome of multiple factors. Isolation of the heart does not do justice to the 
effect of other systems in the body on the heart or vice-versa. The function of an 
isolated heart diminishes over time with an almost 5-10% per hour reduction of 
contractile function and heart rate. 142 Studies within these time points help generate 
useful data but the lil1itation of time is nonetheless a limitation with this technique. 
The second limitation of our study is the use of non-physiological levels of substrates 
in our perfusate. Glucose at 2.5mmollL is not clinically physiological and fatty acids 
at elevated in high adrenergic situations are pathological. Despite being an excellent 
substitute for blood in isolated heart system, one of the major limitations of the 
Krebs- Henseleit buffer is reduced oxygen carrying capacity in comparison to blood. 
The maintenance Of temperature in the normal perfused heart is 110t difficult, but in 
conditions like reduced pressure, it drops rapidly and needs constant monitoring to 
maintain the system at 37°C. 
Another limitation of the study is the applicability of our model in clinical situations. 
HypotenSive acute heart failure is indicative of Takotsubo cardiomyopathy and is 
very rare. Most acute heart failure is caused due to the worsening of chronic heart 
failure and our model focuses on a very specialized hypotensive condition. 
51P and AHF - future work 
The activity of S1 P is mediated via its receptors. 17,143 Future work shall involve the 
delineation of the specific S1 P receptors and their functions in an AHF setting. S1 P 
receptor 3 is mainly involved in the regulation of heart rate, and since the 
improvement in our hearts is mainly in the heart rates, we strongly speculate the 
involvement of S 1 Preceptor 3 in AHF. Besides regulating heart rate, S 1 P exerts its 
effects in various other cardiovascular entities like vascular tone and resistance, 
inflammation and cell survival in other models of cell death.aa S1P is a component of 
high density lipoprotein (HDL) cholesterol and is thought to contribute to the 
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cardioprotective effect of HDl.87,144,145 We would like to measure plasma HDL levels 
in patients with acute heart failure and measure the S1 P content in these molecules. 
Our experiments with S1 P demonstrate three interesting outcomes: 
• S1 P improves functional recovery of the acutely failing heart by activating the 
SAFE pathway. 
• The cytoprotective role of S1 P against apoptosis is via an unknown 
mechanism which merits further work. 
• Combination of S1 P with the metabolic agents not only increased the heart 
rate, but the contractility also. 
S1 P is an enigmatic molecule. Despite the fact that S1 P activates the SAFE pathway 
to elucidate cardioprotection in a heart subjected to ischaemic-reperfusion injury, 
S 1 P also acts as an agent facilitating a crosstalk between SAFE and RISK paths. 102 
The mechanism of this cardioprotection is by phosphorylation of STAT3 which 
translocates to the nucleus and to the mitochondria as well and reduces cell death 
by reducing infarct size. 102 
In our model of de novo AHF, when S1P was administered in the AHF phase in 
absence of adrenaline, it was protective by increasing the heart rate. This protection 
was abrogated when adrenaline was added in the AHF phase. However, S1 P in 
recovery phase improved heart rate despite the presence of adrenaline. This activity 
of S1P was mediated by the SAFE as shown by the increased levels of 
phosphorylated STAT3 in the nucleus, but not in the mitochondrial fraction. 
Reduction of cytochrome C by S 1 P treatment was independent of SAFE pathway in 
our experiments. 
Proposed mechanisms for activity of S1P 
These data indicate more than one mechanisms involved in protection by S1 P. One 
possible mechanism is that S1P acts as an intracellular agent to reduce the cell 
death. Ceramide and S1P belong to the same family, even though their cellular 
functions are opposite. While ceramide promotes apoptosis, S1 P is an anti-
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apoptotiC.8S,88 This celicate balance of ceramide and S1 P acts as a rheostat and 
increased concentrations of intracellular S1 P promote cell survival by its action on 
mobilization of intracellular calcium and activation of phospholipase D.146 We 
suspect that in an acutely failing heart, S1 P exerts its anti-apoptotic effects as an 
intracellular messenner. This hypothesis requires further investigation. 
The findings of this thesis also suggest a possible metabolic effect of S1P when 
used in combination with glucose and insulin. S1 P is shown to be responsible for the 
regulation of glucosl3 stimulated insulin secretion in the pancreatic cells. However, 
the effects of S-I P and GI have never been tested in the heart. In the pancreatic 
cells, high concentration of glucose stimulates the activity of sphingosine kinase, 
thus, producing S 1 P .99 In our model, when administered individually, S 1 P, glucose 
and insulin only improved the heart rate, thus suggesting that they all work on the 
sinus node. However, when given together, they not only increased the heart rate, 
but LV developed pressure as well. We propose that S1P facilitates the uptake of 
glucose in presence of insulin and is energy efficient and hence the contractility is 
improved. This promising hypothesis requires more work. 
Future work with metabolic agents 
As Thorstein Veblen 1said, "The outcome of any serious research can only be to 
make two questions grow where only one grew before." We started this project with 
the idea of setting up and validating a model of acute heart failure but we ended up 
with not just a mod l31, but information about agents involved in the recovery of AHF 
and their possible mechanisms as well. Our experiments examined the effect of 
metabolic and pharmacological agents on recovery against AHF and opened the 
field to many new questions and fascinating opportunities. 
Glucose and insulin improved recovery by elevating the heart rate in our acutely 
failing hearts. The rlrst aim of our future work will be to examine the sinus node in 
AHF and test the effect of glucose and insulin on recovery. Insulin acts via the SAFE 
pathway to provide protection 147; we are keen to see if the metabolic pathways also 
activate the SAFE pathway. In order to measure the uptake of glucose and fatty 
1 TV: 1857-1929. American economist and Sociologist 
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acids in AHF, we shall also measure rates of glycolysis and fatty acid oxidation in the 
AHF phase, both in the presence and absence of adrenaline. 
We used hypotension and extreme substrate changes with an adrenergic stimulus to 
induce acute heart failure, but very few patients present with such harsh 
complications. In sub-Saharan Africa, hypertension is the leading cause of acute 
heart failure and i:3 independent of gender.36 The future work should involve 
establishing and validating two models of hypertensive AHF. First, using the isolated 
hearts, where AHF is induced by acute hypertension, we will raise the height of the 
perfusion column to 170 cm H20. This shall be coupled with changes in substrates 
as described in this thesis and the addition of adrenaline. The effect of increasing the 
height of the perfusion column that induced failure has been studied by Opie72 in 
1965, they found that above a perfusion pressure of 180mmHg, isolated hearts went 
into irreversible failure. The second model shall be in vivo to study the effects on the 
entire organism. To validate an in vivo model, we propose to utilize spontaneously 
hypertensive rats that we shall monitor by echocardiography to confirm chronic heart 
failure and then subject these hearts to AHF on the Langendorff system. Or we could 
use haemorrhage as a model to induce hypotension to test the systemic effects of 
hypotensive AHF in the whole organism. The measurement of biomarkers like B-type 
natriuretic peptide (BNP), pro-BNP, tumor necrosis factor (TNF) a, interleukin-6 (IL-
6), troponin etc will also help us to better understand the progression of the disease. 
Ketones as important fuels (and a possible therapy) against AHF 
Ketones, like amino acids, are substrates for the heart, but their utilization to 
generate ATP is VHry low due to their low concentration in blood. In a chronically 
failing heart, concentration of blood ketones is increased and this elevation is 
proportional to the severity of dysfunction and neurohormonal activation.37 Ketones 
work by inhibiting lhe oxidation of both glucose and fatty acids and the processes 
involved in this activity are not very well understood. The suppression of fatty acid 
oxidation by ketones appears to be independent of malonyl Co-A activity, which 
normally binds to carnitinepalmitoyltransferase1 to inhibit fatty acid oxidation.53,56 In 
working hearts, addition of ketone bodies to glucose increased the efficiency by 36% 
and increased acetyl CoA almost 18-fold.148 Ketones also minimally reduce the 
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oxygen consumption and are therefore good substrates. 29 Ketones are the most 
efficient fuels in adverse conditions, based on the ATP generated per molecule of 
oxygen consumed. 29 In working rat hearts, ketones perfused with glucose showed no 
difference in cardiac function when compared to glucose alone; however, the rate of 
glucose oxidation was reduced. 18 There are no data that examine the effect of 
ketones as substrates in an acutely failing heart. We propose that in AHF where 
glucose metabolism is suppressed by elevated catecholamines and fatty acids, an 
addition of ketones to glucose and insulin will increase functional recovery by 
suppressing fatty acids. 
In advanced CHF, hearts have impaired substrate uptake to generate ATP. 149,150 
Ketone metabolism is preserved in the myocardium while it is diminished in the 
skeletal muscle.15o Given the efficiency of ketones to generate ATP, we propose that 
administration of '<etones in an acutely failing heart (de novo or acute 
decompensated) could be a promising novel therapy in the emergency room to 
salvage the myocardium. 
SUMMARY OF EXPERIMENTS AND FUTURE WORK 
Table 8-1: Summary of outcomes of experiments and future work 
Acute heart failure 
(AHF) 
: Possible treatments i 
I Glucose-Insulin (Gil 
i infusion 
Sphingosine-1­






Outcome of treatment 
Heart rate (HR) improvement, 
reduction of LVEDP, energy efficient 
fuel, reduces damage caused by 
catecholamines 
HR improvement by possible 
stimulation of S 1 Preceptor 3, 
reduces apoptosis 
HR improvement, improves 




More efficient in generation of ATP 
than glucose or fatty acids, future 
[___~_____________~____K_e_IDnes ____~_____________w~o~rk~ _________~ 
(HR~ heart rate; LVE.DP~ left ventricular end diastolic pressure; S1P~ sphingosine~1-
phosphate; A TP~ adenosine triphosphate) 
Future potential benefits of glucose, insulin and S1P on AHF 
AHF is the most common cause of cardiovascular events leading to hospitalization in 
the elderly.23.43 AHF can either be the exacerbation of chronic heart failure or may be 
de novo. However, the most common cause of AHF admissions is the worsening of 
CHF. 19,39 Monitorin~1 of AHF clinically can be broadly divided into three phases: 
immediate treatment of symptoms and stabilization of patient, in-hospital 
management and post-discharge period where the risk of re-hospitalization is very 
high.151AHF is a clinically complex disease and despite the numerous trials,66 the 
outcome for patients appears dismal. A subtype of de novo AHF, Takotsubo 
cardiomyopathy which is also called stress cardiomyopathy or "broken heart 
syndrome" was first described in Japan, but has grown since and many cases are 
now reported globally.45.46 This is characterized by acute transient left ventricular 
failure caused by acute emotional stress.46 One of the major reasons of the lack of 
new therapies ancl treatments is the lack of basic research coupled with the 
uncertainty regarding the metabolism and physiological pathways involved in the 
progreSSion and recovery of AHF, mostly in de novo AHF. 
The understanding of de novo AHF and the metabolism involved may be explained 
using a hypothetical example of an early humanoid hunter in the plains of Africa who 
had to endure many stressful circumstances including extreme physical exercise, 
high adrenergic stress and often, loss of blood. The extreme surroundings may have 
led to the development of protective metabolic pathways to counter the adverse 
effects of catecholamines and fatty acids.6 AHF similarly is a stress situation which 
would ideally elevate the levels of catecholamines which in turn are deleterious to 
the heart as they promote the up-regulation of fatty acid oxidation. Our model of de 
novo AHF follows this example and we induced AHF by lowering the perfusion 
pressure and increasing FFA in the perfusate while simultaneously lowering the 
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glucose concentration. We explore specific conditions which we believe are 
imperative in the metabolism for progression and treatment of the disease. 
The metabolic experiments described in this thesis strongly point to the 
cardioprotective effects of administration of glucose-insulin (GI). The addition of 
adrenaline in the AHF phase of our experiments had deleterious effects on the 
recovery and can correlate with a possible catecholamine spike in patients despite 
the lack of actual measurements in the clinical setting. AHF, whether de novo or 
acute decompensation of CHF is a stress stimulus, should ideally elevate the blood 
concentration of catecholamines leading to the up-regulation of fatty acid oxidation. 
Based on the experiments in this thesis, the addition of GI might be protective to the 
acutely failing heart. In Takotsubo cardiomyopathy which is a sub-type of AHF, 
catecholamines are known to be supra-physiological which is believed to cause 
acute dilation of the left ventricle.46.152 The mechanisms leading to this dilation are 
still unknown however, several hypotheses have been suggested,45 the most 
promising of them being the myocardial stunning as a direct effect of sympathetic 
activity, causing a calcium overload and leading to contraction band necrosis.41 
Reasons why metabolic therapy could work 
Visualizing AHF as metabolic abnormalities where impaired substrate utilization in 
presence of increased sympathetic drive may help us design new therapies and 
markers to predict outcomes in patients. J Cohn in 1984 clearly showed that plasma 
concentration of epinephrine was a better marker of prognosis in patients of CHF.153 
Elevated catecholarnines promoting uptake of FFA in CHF prompted to the discovery 
of various drugs like trimetazidine which partially shift the metabolism from fatty 
acids to glucose in a failing heart to improve ATP production. 27 Data from our studies 
point to the unfavorable effects of adrenaline which are partially countered by the 
addition of GI to the heart. Testing a drug like trimetazidine in the post discharge 
"high risk" period may be beneficial as it could improve the heart function by altering 
the metabolism, especially in patients with acute decompensated HF. However, 
more work needs to be done before such theories are tested in patients. Besides the 
ATP production, tre infusion of GI also improves the activity of sinus node, as 
observed by Senges et 81 in 1982 where it was the glucose- insulin that improved the 
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sinus node activity and not potassium.127 Data from our studies also show an 
improvement in sinus node activity by increasing heart rate in presence of glucose-
insulin. 
The possible effect of S1 P in protection elucidated by GI makes it a potential 
metabolic mediator, besides being an anti-apoptotic molecule. Since S1 P is a prime 
component of HDL, monitoring the HDL levels in patients with AHF might be a useful 
diagnostic measure for the clinicians. 
Regarding potential application to patients, this thesis has successfully presented the 
first ever de novo AHF animal model and points to certain factors which may help in 
the clinical setting. Blood pressure, heart rate and monitoring in an Intensive Care 
Unit are already standard measures for patients with AHF. Intravenous 
catecholamine therapy with agents such as dobutamine, dopamine, and milrinone, is 
often used to support the failing left ventricle 154 but such agents may have side-
effects such as oXY!Jen-wastage that are linked to the catecholamine-elevated blood 
FFA levels. The data presented in this thesis suggest investigation of alternate 
modes of stimulating depressed sinus node activity in AHF,49 such as the 
administration of intravenous glucose-insulin or S-1-P. 
In summary, this PhD Project has used the well-established Langendorff perfusion 
system to study acute heart failure. It defines the basic principles of future molecular 
and metabolic approach which could potentially not only help in the better 
understanding of the disease mechanism but also in the development of novel 
treatments. This thesis has explored aspects of the metabolic and molecular therapy 
of acute heart failure using a simple reproducible isolated heart model, and the 
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